<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cell Physiol</journal-id><journal-id journal-id-type="iso-abbrev">J. Cell. Physiol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1097-4652</journal-id><journal-id journal-id-type="publisher-id">JCP</journal-id><journal-title-group><journal-title>Journal of Cellular Physiology</journal-title></journal-title-group><issn pub-type="ppub">0021-9541</issn><issn pub-type="epub">1097-4652</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6916329</article-id><article-id pub-id-type="doi">10.1002/jcp.29176</article-id><article-id pub-id-type="publisher-id">JCP29176</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research Articles</subject></subj-group></article-categories><title-group><article-title>Autophagy inhibition via <italic>Becn1</italic> downregulation improves the mesenchymal stem cells antifibrotic potential in experimental liver fibrosis</article-title><alt-title alt-title-type="left-running-head">WANG <sc>et al.</sc></alt-title></title-group><contrib-group><contrib id="jcp29176-cr-0001" contrib-type="author"><name><surname>Wang</surname><given-names>Hang Yu</given-names></name><xref ref-type="aff" rid="jcp29176-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jcp29176-cr-0002" contrib-type="author"><name><surname>Li</surname><given-names>Can</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5746-6368</contrib-id><xref ref-type="aff" rid="jcp29176-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="jcp29176-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jcp29176-cr-0003" contrib-type="author"><name><surname>Liu</surname><given-names>Wei Hua</given-names></name><xref ref-type="aff" rid="jcp29176-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jcp29176-cr-0004" contrib-type="author"><name><surname>Deng</surname><given-names>Feng Mei</given-names></name><xref ref-type="aff" rid="jcp29176-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="jcp29176-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jcp29176-cr-0005" contrib-type="author"><name><surname>Ma</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="jcp29176-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jcp29176-cr-0006" contrib-type="author"><name><surname>Guo</surname><given-names>Li Na</given-names></name><xref ref-type="aff" rid="jcp29176-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jcp29176-cr-0007" contrib-type="author"><name><surname>Kong</surname><given-names>De Hua</given-names></name><xref ref-type="aff" rid="jcp29176-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jcp29176-cr-0008" contrib-type="author"><name><surname>Hu</surname><given-names>Kang An</given-names></name><xref ref-type="aff" rid="jcp29176-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jcp29176-cr-0009" contrib-type="author"><name><surname>Liu</surname><given-names>Qin</given-names></name><xref ref-type="aff" rid="jcp29176-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jcp29176-cr-0010" contrib-type="author"><name><surname>Wu</surname><given-names>Jiang</given-names></name><xref ref-type="aff" rid="jcp29176-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jcp29176-cr-0011" contrib-type="author" corresp="yes"><name><surname>Sun</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="jcp29176-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="jcp29176-aff-0003">
<sup>3</sup>
</xref><address><email>jingsunn@126.com</email></address></contrib><contrib id="jcp29176-cr-0012" contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Yi Lun</given-names></name><xref ref-type="aff" rid="jcp29176-aff-0003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="jcp29176-aff-0004">
<sup>4</sup>
</xref><address><email>yilunliu@foxmail.com</email></address></contrib></contrib-group><aff id="jcp29176-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Key Laboratory of Xingjiang Phytomedicine Resources and Utilization, Ministry of Education, School of Pharmacy</named-content>
<institution>Shihezi University</institution>
<city>Shihezi</city>
<country country="CN">China</country>
</aff><aff id="jcp29176-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Pathology and Pathophysiology</named-content>
<institution>Chengdu Medical College</institution>
<city>Chengdu</city>
<country country="CN">China</country>
</aff><aff id="jcp29176-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Sichuan Clinical Research Center for Geriatrics</named-content>
<institution>The First Affiliated Hospital of Chengdu Medical College</institution>
<city>Chengdu</city>
<country country="CN">China</country>
</aff><aff id="jcp29176-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Surgery</named-content>
<institution>The First Affiliated Hospital of Chengdu Medical College</institution>
<city>Chengdu</city>
<country country="CN">China</country>
</aff><aff id="jcp29176-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Deep&#x02010;Underground Medicine Laboratory</named-content>
<institution>West China Hospital of Sichuan University</institution>
<city>Chengdu</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold> Jing Sun, Department of Pathology and Pathophysiology, Chengdu Medical College, 783 Xindu Avenue, Chengdu 610500, China.<break/>
Email: <email>jingsunn@126.com</email><break/>
Yi L. Liu, Sichuan Clinical Research Center for Geriatrics, The First Affiliated Hospital of Chengdu Medical College, 278 Bao Guang Avenue, Chengdu 610500, China.<break/>
Email: <email>yilunliu@foxmail.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2020</year></pub-date><volume>235</volume><issue>3</issue><issue-id pub-id-type="doi">10.1002/jcp.v235.3</issue-id><fpage>2722</fpage><lpage>2737</lpage><history><date date-type="received"><day>10</day><month>4</month><year>2019</year></date><date date-type="accepted"><day>26</day><month>8</month><year>2019</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2019 Wiley Periodicals, Inc. <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2019 The Authors. <italic>Journal of Cellular Physiology</italic> published by Wiley Periodicals, Inc.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JCP-235-2722.pdf"/><abstract><title>Abstract</title><p>Liver fibrosis (LF) is the result of a vicious cycle between inflammation&#x02010;induced chronic hepatocyte injury and persistent activation of hepatic stellate cells (HSCs). Mesenchymal stem cell (MSC)&#x02010;based therapy may represent a potential remedy for treatment of LF. However, the fate of transplanted MSCs in LF remains largely unknown. In the present study, the fate and antifibrotic effect of MSCs were explored in a LF model induced by CCl<sub>4</sub> in mouse. Additionally, MSCs were stimulated in vitro with LF&#x02010;associated factors, tumor necrosis factor&#x02010;&#x003b1; (TNF&#x02010;&#x003b1;), interferon&#x02010;&#x003b3; (IFN&#x02010;&#x003b3;), and transforming growth factor&#x02010;&#x003b2;1 (TGF&#x02010;&#x003b2;1), to mimic the LF microenvironment. We unveiled that MSCs exhibited autophagy in response to the LF microenvironment through <italic>Becn1</italic> upregulation both in vivo and in vitro. However, autophagy suppression induced by <italic>Becn1</italic> knockdown in MSCs resulted in enhanced antifibrotic effects on LF. The improved antifibrotic potential of MSCs may be attributable to their inhibitory effects on T lymphocyte infiltration, HSCs proliferation, as well as production of TNF&#x02010;&#x003b1;, IFN&#x02010;&#x003b3;, and TGF&#x02010;&#x003b2;1, which may be partially mediated by elevated paracrine secretion of PTGS2/PGE<sub>2</sub>. Thus, autophagy manipulation in MSCs may be a novel strategy to promote their antifibrotic efficacy.</p></abstract><abstract abstract-type="graphical"><p>We found that mesenchymal stem cells (MSCs) underwent autophagy in response to liver fibrosis (LF) microenvironment by upregulating BECN1 expression. Inhibition of autophagy induced by Becn1 knockdown in MSCs promoted their antifibrotic efficacy on CCl<sub>4</sub>&#x02010;induced LF. The improved antifibrotic potential of MSCs might be attributed to their inhibitory effects on T lymphocyte infiltration, hepatic stellate cell proliferation, as well as production of TNF&#x02010;&#x003b1;, IFN&#x02010;&#x003b3;, and TGF&#x02010;&#x003b2;1, which might be partially mediated by elevated paracrine secretion of PTGS2/PGE<sub>2</sub>.
<boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xlink:href="JCP-235-2722-g008.jpg" position="anchor" id="nlm-graphic-1" orientation="portrait"/></boxed-text>
</p></abstract><kwd-group><kwd id="jcp29176-kwd-0001">autophagy</kwd><kwd id="jcp29176-kwd-0002">hepatic stellate cells</kwd><kwd id="jcp29176-kwd-0003">immunosuppression</kwd><kwd id="jcp29176-kwd-0004">liver fibrosis</kwd><kwd id="jcp29176-kwd-0005">mesenchymal stem cells</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Scientific Research Project of the Development and Regeneration Key Laboratory of Sichuan Province</funding-source><award-id>SYS15&#x02010;004</award-id><award-id>SYS15&#x02010;008</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>National Natural Science Foundation of China </institution><institution-id institution-id-type="open-funder-registry">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>81560566</award-id><award-id>81570558</award-id></award-group><award-group id="funding-0003"><funding-source>Applied Basic Research Programs of Science and Technology Department of Sichuan Province</funding-source><award-id>2017JY0150</award-id><award-id>2017JY0304</award-id></award-group></funding-group><counts><fig-count count="8"/><table-count count="1"/><page-count count="16"/><word-count count="9086"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2020</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.3 mode:remove_FC converted:17.12.2019</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jcp29176-cit-0049">
<string-name>
<surname>Wang</surname>
<given-names>HY</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>WH</given-names>
</string-name>, et al. <article-title>Autophagy inhibition via <italic>Becn1</italic> downregulation improves the mesenchymal stem cells antifibrotic potential in experimental liver fibrosis</article-title>. <source xml:lang="en">J Cell Physiol</source>. <year>2019</year>;<volume>235</volume>:<fpage>2722</fpage>&#x02013;<lpage>2737</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.29176</pub-id>
<pub-id pub-id-type="pmid">31508820</pub-id></mixed-citation>
</p><fn-group><fn id="jcp29176-note-0001"><p>Hang Y. Wang, Can Li, and Wei H. Liu contributed equally to this work.</p></fn></fn-group></notes></front><body><sec id="jcp29176-sec-0010"><label>1</label><title>INTRODUCTION</title><p>Liver fibrosis (LF), characterized by extracellular matrix (ECM) protein production and accumulation, is a vicious cycle between chronic inflammation&#x02010;induced persistent parenchymal cell injury and activation of consequent wound&#x02010;healing responses executed mainly by activated myofibroblasts, which define the LF microenvironment (Tsuchida &#x00026; Friedman, <xref rid="jcp29176-bib-0043" ref-type="ref">2017</xref>). Genetic techniques have provided strong evidence that primed hepatic stellate cells (HSCs) are the prominent cellular origin of matrix protein&#x02010;secreting myofibroblasts (Lee, Wallace, &#x00026; Friedman, <xref rid="jcp29176-bib-0022" ref-type="ref">2015</xref>; Trautwein, Friedman, Schuppan, &#x00026; Pinzani, <xref rid="jcp29176-bib-0042" ref-type="ref">2015</xref>). Genetic lineage&#x02010;tracing analysis performed by Kramann et al. (<xref rid="jcp29176-bib-0021" ref-type="ref">2015</xref>) strongly suggested that glioma&#x02010;associated oncogene homolog 1 (<italic>Gli1</italic>) is an in vivo marker of myofibroblast progenitors; thus, HSCs can be traced in vivo using a <italic>Gli1</italic> genetic lineage&#x02010;tracing technique. In addition, both the occurrence and progression of LF are closely related to T&#x02010;cell&#x02010;mediated immune responses (Pesce et al., <xref rid="jcp29176-bib-0030" ref-type="ref">2006</xref>; Wynn, <xref rid="jcp29176-bib-0047" ref-type="ref">2004</xref>).</p><p>Multiple researches have consolidated the beneficial efficacy of mesenchymal stem cells (MSCs) on treatment of varied inflammatory disease (L. Bai et al., <xref rid="jcp29176-bib-0004" ref-type="ref">2012</xref>; Rocheteau et al., <xref rid="jcp29176-bib-0035" ref-type="ref">2015</xref>; Swart et al., <xref rid="jcp29176-bib-0041" ref-type="ref">2015</xref>), and the therapeutic effects of MSCs are largely attributable to their profound immunoinhibitive capacity (Horton et al., <xref rid="jcp29176-bib-0019" ref-type="ref">2013</xref>; Wang, Chen, Cao, &#x00026; Shi, <xref rid="jcp29176-bib-0045" ref-type="ref">2014</xref>). Nevertheless, the uncertainty of the transplanted MSCs poses critical challenge for obtaining predictable therapeutic effects in vivo. The in vivo inflammatory microenvironment is a pivotal necessity for MSCs to execute their immunomodulatory functions (Ren et al., <xref rid="jcp29176-bib-0034" ref-type="ref">2008</xref>). The interactions between MSCs and inflammatory microenvironment regulate the immunomodulatory properties of MSCs (Y. Liu et al., <xref rid="jcp29176-bib-0025" ref-type="ref">2011</xref>). However, few studies have evaluated the mechanisms through which the inflammatory microenvironment of LF controls the immunoregulatory capability of MSCs.</p><p>Autophagy is a highly conservative eukaryotic degradative process, which is a requisite for replying and adapting to environmental alterations (Cadwell, <xref rid="jcp29176-bib-0006" ref-type="ref">2016</xref>). Autophagy&#x02010;related genes (<italic>Atg</italic>s), including <italic>Atg7, Atg12, Atg5</italic> as well as <italic>Becn1,</italic> regulate autophagosome maturation (Antonioli, Di Rienzo, Piacentini, &#x00026; Fimia, <xref rid="jcp29176-bib-0003" ref-type="ref">2017</xref>). Emerging evidence has confirmed a close link between autophagy and immunomodulation has been confirmed by emerging evidence (Shibutani, Saitoh, Nowag, M&#x000fc;nz, &#x00026; Yoshimori, <xref rid="jcp29176-bib-0040" ref-type="ref">2015</xref>). Some studies unveiled that inflammatory microenvironment hindered the immunosuppressive properties of MSCs by priming autophagy (Dang et al., <xref rid="jcp29176-bib-0009" ref-type="ref">2014</xref>). Therefore, we hypothesized that the LF microenvironment could also interact with the autophagic and immunoregulatory potential of MSCs and that modulation of autophagy may in turn influence the therapeutic effect of MSCs in LF.</p><p>In the current study, we assessed the autophagy activity in transplanted MSCs triggered by hepatic microenvironment in vivo. We also examined the effect of stimulating MSCs by LF&#x02010;related cytokines, including tumor necrosis factor (TNF)&#x02010;&#x003b1;, interferon&#x02010;&#x003b3; (IFN&#x02010;&#x003b3;), and transforming growth factor&#x02010;&#x003b2;1 (TGF&#x02010;&#x003b2;1) on autophagy&#x02010;related gene expression. Furthermore, we evaluated the effect of autophagy inhibition on the antifibrotic activity of MSCs. The findings of this study are expected to provide novel insights into the relationship between autophagy and the immunomodulatory effects of MSCs, and indicate whether autophagy could be considered as a promising therapeutic target for MSCs for treating LF.</p></sec><sec id="jcp29176-sec-0020"><label>2</label><title>MATERIALS AND METHODS</title><sec id="jcp29176-sec-0030"><label>2.1</label><title>Isolation and culture of MSCs</title><p>MSCs were enriched from the bone marrow of male C57BL/6 mice and cultured in DMEM&#x02010;low glucose (cat. no. 01&#x02010;051&#x02010;1AC5; BI, Kibbutz Beit Haemek, Israel) containing 10% fetal bovine serum (FBS, cat. no. 10099&#x02010;141; Gibco, Grand Island, NY). MSCs were seeded at 2&#x02009;&#x000d7;&#x02009;10<sup>6</sup>&#x02009;cells/100&#x02010;mm culture dish (cat. no. 07&#x02010;3100; Biologix Group, Jiangsu, China) and cultured for 72&#x02009;hr in an incubator containing 5% CO<sub>2</sub> at 37&#x000b0;C. To remove floating cells, on the second day, the cultures were rinsed twice with phosphate&#x02010;buffered saline (PBS). The methods for MSC characterization are described in the Supporting Information Materials. Phenotypic characterization of MSCs is presented in Supporting Information Data.</p></sec><sec id="jcp29176-sec-0040"><label>2.2</label><title>Short hairpin RNA (shRNA)&#x02010;mediated <italic>Becn1</italic> stable knockdown</title><p>The specific <italic>Becn1</italic> shRNA was purchased from Geneplay Biomedical Technology (Suzhou, China). The nucleotide sequences were as follows: Plko.1&#x02010;EGFP&#x02010;<italic>Becn1</italic>&#x02010;shRNA, 5&#x02032;&#x02010;GGAGAAAGGCAAGATTGAAGA&#x02010;3&#x02032;; scrambled control (shNC), 5&#x02032;&#x02010;CCTAAGGTTAAGTCGCCCTCG&#x02010;3&#x02032;. A multiplicity of infection of 200 of lentiviruses was utilized for MSC infection.</p></sec><sec id="jcp29176-sec-0050"><label>2.3</label><title>In vitro MSC treatment</title><p>MSCs were starved or treated with TNF&#x02010;&#x003b1; (20&#x02009;ng/ml, cat. no. 50349&#x02010;MNAE; SB, Beijing, China), IFN&#x02010;&#x003b3; (50&#x02009;ng/ml, cat. no. 50709&#x02010;MNAH; SB), or TGF&#x02010;&#x003b2;1 (10&#x02009;ng/ml, cat. no. 7666&#x02010;MB&#x02010;005; R&#x00026;D Systems, Minneapolis, MN) for 0&#x02013;24&#x02009;hr and then subjected to western blot analysis of microtubule&#x02010;associated protein 1A/1B light chain 3 (MAP1LC3). Cells incubated under starvation served as a positive control. MSCs were stimulated with TNF&#x02010;&#x003b1; (20&#x02009;ng/ml), IFN&#x02010;&#x003b3; (50&#x02009;ng/ml), and TGF&#x02010;&#x003b2;1 (10&#x02009;ng/ml) alone or in different combinations for 6&#x02009;hr. Subsequently, MAP1LC3&#x02010;I, MAP1LC3&#x02010;II, and p62 expression levels were measured using western blot analysis. Autophagosome formation was detected by transmission electron microscopy, and MAP1LC3 dot formation in MSCs was visualized by immunofluorescence staining. Additionally, shNC&#x02010;MSCs and sh<italic>Becn1</italic>&#x02010;MSCs were incubated in absence or presence of TNF&#x02010;&#x003b1; (20&#x02009;ng/ml), IFN&#x02010;&#x003b3; (50&#x02009;ng/ml), or TGF&#x02010;&#x003b2;1 (10&#x02009;ng/ml) for 6&#x02009;hr. Subsequently, <italic>Becn1</italic> messenger RNA (mRNA) levels were measured by quantitative reverse transcription polymerase chain reaction (qRT&#x02010;PCR). In addition, protein expression levels of MAP1LC3&#x02010;I, MAP1LC3&#x02010;II, p62, and BECN1 were detected using immunoblotting. To further evaluate the effects of <italic>Becn1</italic> knockdown on expression of prostaglandin&#x02010;endoperoxide synthase 2 (PTGS2) in MSCs, shNC&#x02010;MSCs were treated with or without 3&#x02010;methyladenine (3&#x02010;MA, cat. no. M9281; Sigma, St. Louis, MO), and sh<italic>Becn1</italic>&#x02010;MSCs were incubated for indicated time with or without rapamycin (cat. no. 553210; Sigma) under stimulation with TNF&#x02010;&#x003b1; (20&#x02009;ng/ml), IFN&#x02010;&#x003b3; (50&#x02009;ng/ml), and TGF&#x02010;&#x003b2;1 (10&#x02009;ng/ml) for 12&#x02009;hr.</p></sec><sec id="jcp29176-sec-0060"><label>2.4</label><title>Transmission electron microscopy</title><p>After starvation or combined treatment of TNF&#x02010;&#x003b1;, IFN&#x02010;&#x003b3;, and TGF&#x02010;&#x003b2;1, MSCs were rinsed with PBS and fixed with 2% glutaraldehyde (cat. no. G5882; Sigma) in 0.1&#x02009;M phosphate buffer (pH 7.2) for 2&#x02009;hr at 4&#x000b0;C. The cells were postfixed with 1% osmic acid for another 2&#x02009;hr at 4&#x000b0;C, followed by dehydration using ethanol in graded concentrations. Subsequently, the sections were incubated with uranylacetate and lead citrate (cat. no. 15326; Sigma), and images were acquired using an Olympus EM208S transmission electron microscope (Olympus, Tokyo, Japan).</p></sec><sec id="jcp29176-sec-0070"><label>2.5</label><title>LF model induction and MSC transplantation</title><p>Male SPF C57BL/6 mice (2 months of age, average body weight: 25&#x02009;g) were obtained from Chengdu Dossy Experimental Animals Co. Ltd. (Chengdu, China). <italic>Gli1</italic>CreER<sup>t2</sup> (cat. no. 007913) and Rosa26<italic>tdTomato</italic> (cat. no. 007909) mice were obtained from Jackson Laboratories (Bar Harbor, ME). For lineage&#x02010;tracing studies, 6&#x02013;7&#x02010;week&#x02010;old male mice underwent three intraperitoneal injections of tamoxifen (cat. no. 06734; Sigma) at a dose of 0.1&#x02009;mg/kg body weight in corn oil/3% ethanol 10 days before LF induction. Detailed information on identification of <italic>Gli1</italic> genetic lineage&#x02010;tracing mice is given in the Supporting Information Materials. LF mice were induced by CCl<sub>4</sub> olive oil solution (CCl<sub>4</sub>:olive oil&#x02009;=&#x02009;1:3) via intraperitoneal injection at a concentration of 4&#x02009;ml/kg twice per week for 5 consecutive weeks (CCl<sub>4</sub> mice). Accordingly, the control group mice were then subjected to the same concentration of olive oil by intraperitoneal injection (oil mice).</p><p>MSCs of passage 5 (P5) infected with lentivirus&#x02010;control shRNA were transplanted into oil mice and CCl<sub>4</sub> mice at a density of 1&#x02009;&#x000d7;&#x02009;10<sup>6</sup>&#x02009;cells in 100&#x02009;&#x003bc;l normal saline per mouse via the tail vein (on Week 5, <italic>n</italic>&#x02009;=&#x02009;8). Mice were euthanized at 0 and 72&#x02009;hr after cell administration. In subsequent in vivo experiments, 32 mice were randomly designated into four groups with comparable mean body weights; the groups were as follows: oil&#x02009;+&#x02009;PBS, CCl<sub>4</sub>&#x02009;+&#x02009;PBS, CCl<sub>4</sub>&#x02009;+&#x02009;shNC, and CCl<sub>4</sub>&#x02009;+&#x02009;sh<italic>Becn1</italic> groups (<italic>n</italic>&#x02009;=&#x02009;8 each). In the CCl<sub>4</sub>&#x02009;+&#x02009;PBS, CCl<sub>4</sub>&#x02009;+&#x02009;shNC, and CCl<sub>4</sub>&#x02009;+&#x02009;sh<italic>Becn1</italic> groups, CCl<sub>4</sub>&#x02010;induced LF model mice were subjected to weekly administration of PBS, shNC&#x02010;MSCs (1&#x02009;&#x000d7;&#x02009;10<sup>7</sup>/ml, P5), or sh<italic>Becn1</italic>&#x02010;MSCs (1&#x02009;&#x000d7;&#x02009;10<sup>7</sup>/ml, P5) from Weeks 3 to 5 via the tail vein. The oil&#x02009;+&#x02009;PBS group underwent PBS administration with the same volume and sequence as the treatment group after oil treatment. The mice were killed 3 days after cell transplantation. In some in vivo experiments, 32 mice were randomly allocated to four groups, that is, oil&#x02009;+&#x02009;shNC, oil&#x02009;+&#x02009;sh<italic>Becn1</italic>, CCl<sub>4</sub>&#x02009;+&#x02009;shNC, and CCl<sub>4</sub>&#x02009;+&#x02009;sh<italic>Becn1</italic> groups (<italic>n</italic>&#x02009;=&#x02009;8 each). shNC&#x02010;MSCs or sh<italic>Becn1</italic>&#x02010;MSCs were administered to oil mice or CCl<sub>4</sub> mice (on Week 5) via tail vein. The mice were euthanized 3 days after cell transplantation for subsequent evaluation of the localization of exogenous MSCs in the liver.</p><p>All animal operations were conducted in line with the Chinese Guidelines for Use of Experimental Animals, which was also approved by the Animal Experimentation Ethics Committee, the First Affiliated Hospital of Chengdu Medical College, China.</p></sec><sec id="jcp29176-sec-0080"><label>2.6</label><title>Sirius red, Masson, and hematoxylin and eosin (HE) staining</title><p>After being injected with PBS, shNC&#x02010;MSCs, or sh<italic>Becn1</italic>&#x02010;MSCs, mice were euthanized and liver tissues were obtained. The liver tissues were embedded in paraffin following alcohol dehydration. Sections of liver were then subjected to HE staining (cat. no. KGA224; KeyGEN BioTECH, Nanjing, China), Masson staining (cat. no. HT15&#x02010;1KT; Sigma), or Sirius red staining (cat. no. G1471; Solarbio).</p></sec><sec id="jcp29176-sec-0090"><label>2.7</label><title>Immunofluorescence staining</title><p>Mice were euthanized, and livers were resected, embedded into OCT (cat. no. 4583; Sakura), and stored at &#x02212;80&#x000b0;C. Following cutting, frozen sections were permeabilized using 0.5% Triton X&#x02010;100 (cat. no. ST795; Beyotime, Shanghai, China) and blocked with 5% bovine serum albumin (BSA, cat. no. 9048&#x02010;46&#x02010;8; Amresco, Solon, OH). Subsequently, the sections were incubated with anti&#x02010;MAP1LC3&#x02010;A/B (cat. no. 4108S; Cell Signaling Technology, Danvers, MA), anti&#x02010;CD4 (cat. no. 550280; BD Biosciences, San Jose, CA), anti&#x02010;CD8 (cat. no. ab22378; Abcam, Cambridge, MA), and anti&#x02010;&#x003b1;&#x02010;smooth muscle actin (SMA) antibodies (cat. no. CBL171; Millipore, Billerica, MA) overnight at 4&#x000b0;C. The sections were rinsed with phosphate&#x02010;buffered saline with Tween 20 (PBST) and incubated with Cy3&#x02010;labeled secondary antibodies (cat. no. A0516; Beyotime), Alexa 488&#x02010;conjugated antibodies (cat. no. A0428; Beyotime), and 4&#x02032;,6&#x02010;diamidino&#x02010;2&#x02010;phenylindole (DAPI; cat. no. C1002; Beyotime). The sections were observed using fluorescence microscopy (TCS SP5; Leica Microsystems, Wetzlar, Germany). For in vitro analysis, the cells were fixed with 4% paraformaldehyde followed by permeability with 0.1% Triton X&#x02010;100 and blocked with 5% BSA. The cells were incubated with anti&#x02010;MAP1LC3&#x02010;A/B antibodies overnight at 4&#x000b0;C. Cells were incubated with Cy3&#x02010;labeled secondary antibodies (cat. no. A0516; Beyotime) and DAPI (cat. no. C1002; Beyotime) followed by PBST washes. The slides were examined under a fluorescence microscope, and images were obtained.</p></sec><sec id="jcp29176-sec-0100"><label>2.8</label><title>Western blot analysis</title><p>Total protein from 100&#x02009;mg mouse liver tissues and MSCs subjected to the above&#x02010;mentioned treatments was obtained using RIPA lysis buffer with the protein inhibitor phenylmethylsulfonyl fluoride (cat. no. ST506; Beyotime). The total protein was quantified using a BCA quantification kit (cat. no. P0010; Beyotime). Proteins were separated using sodium dodecyl sulfate&#x02010;polyacrylamide gel electrophoresis. The proteins in gel were shifted to PVDF membranes (cat. no. ISEQ. 00005; Millipore) for 90&#x02009;min. Membranes were incubated with 5% milk blocking solution for 60&#x02009;min and then with primary antibodies against MAP1LC3&#x02010;A/B (cat. no. 4108S; Cell Signaling Technology), GAPDH (cat. no. 60004&#x02010;1; Proteintech, Wuhan, China), BECN1 (cat. no. 3738S; Cell Signaling Technology), PTGS2 (cat. no. SC&#x02010;166475; Santa Cruz Biotechnology, Santa Cruz, CA), p62 (cat. no. 88588; Cell Signaling Technology), and &#x003b1;&#x02010;SMA (cat. no. CBL171; Millipore) overnight at 4&#x000b0;C. Membranes were then thoroughly rinsed by TBS&#x02010;T and subjected to incubation of peroxidase&#x02010;labeled secondary antibodies (cat. no. SA00001&#x02010;1; Proteintech) for 1&#x02009;hr at room temperature. The membranes were rinsed by TBS&#x02010;T and then incubated with chemiluminescent HRP substrate (cat. no. WBKLSO100; Millipore). Proteins were detected with a chemiluminescence apparatus (Bio&#x02010;Rad, Hercules, CA).</p></sec><sec id="jcp29176-sec-0110"><label>2.9</label><title>Measurement of liver hydroxyproline content</title><p>Following the manufacturer's instructions, liver hydroxyproline levels were quantified by hydroxyproline detection kit (Nanjing JanCheng Biochemical Institute, Nanjing, China).</p></sec><sec id="jcp29176-sec-0120"><label>2.10</label><title>Measurement of serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels</title><p>Serum concentrations of AST and ALT were detected to estimate the degree of hepatic injury caused by CCl<sub>4</sub> administration. Mice were anesthetized as described above, and 0.5&#x02009;ml blood was obtained from the eye sockets of mice, followed by 10&#x02009;min of centrifugation at 3,000&#x02009;rpm. Based on the provided protocol, serum levels of AST and ALT were assessed by diagnostic quantification kits (cat. nos. C010&#x02010;2 and C009&#x02010;2; Nanjing JianCheng Bioengineering Institute, Nanjing, China).</p></sec><sec id="jcp29176-sec-0130"><label>2.11</label><title>Coculture of MSCs and HSCs</title><p>MSCs and HSCs were cocultured in a Transwell coculture system (12&#x02010;mm diameter; 0.4&#x02010;mm pore size, cat. no. G3401; Corning, Corning, NY) with DMEM&#x02010;low glucose containing 10% FBS. Briefly, HSCs at a density of 5&#x02009;&#x000d7;&#x02009;10<sup>4</sup>&#x02009;cells/well were cultivated in the bottom chambers of 24&#x02010;well plates, and MSCs at a density of 2.5&#x02009;&#x000d7;&#x02009;10<sup>3</sup>&#x02009;cells/well were seeded on the Transwell membrane inserts. Three groups were evaluated, that is, control, HSCs&#x02009;+&#x02009;shNC&#x02010;MSC, and HSCs&#x02009;+&#x02009;sh<italic>Becn1</italic>&#x02010;MSC groups, with four wells per group. The HSCs were collected for analysis of proliferation and procollagen type I &#x003b1;1 secretion after coculturing for 24, 48, and 72&#x02009;hr.</p></sec><sec id="jcp29176-sec-0140"><label>2.12</label><title>Enzyme&#x02010;linked immunosorbent assay (ELISA)</title><p>After coculture with MSCs for 72&#x02009;hr, HSCs were collected, and supernatants were obtained to determine secretion of procollagen type I &#x003b1; I (cat. no. ab210579; Abcam) using an ELISA kit. The absorbance (OD value) was measured at 450&#x02009;nm. shNC&#x02010;MSCs and sh<italic>Becn1</italic>&#x02010;MSCs were incubated with TNF&#x02010;&#x003b1; (20&#x02009;ng/ml), IFN&#x02010;&#x003b3; (50&#x02009;ng/ml), and TGF&#x02010;&#x003b2;1 (10&#x02009;ng/ml) alone or in combination for 24&#x02009;hr. Supernatants were then obtained to detect prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) secretion using a PGE<sub>2</sub> ELISA kit (cat. no. KGE004B; R&#x00026;D Systems). For in vivo experiments, the levels of serum PGE<sub>2</sub>, TNF&#x02010;&#x003b1;, TGF&#x02010;&#x003b2;1, and IFN&#x02010;&#x003b3; were determined using PGE<sub>2</sub>, TNF&#x02010;&#x003b1; (cat. no. KE10002; Proteintech), IFN&#x02010;&#x003b3; (cat. no. KE10001; Proteintech), and TGF&#x02010;&#x003b2;1 (cat. no. KE10005; Proteintech) ELISA kits.</p></sec><sec id="jcp29176-sec-0150"><label>2.13</label><title>Real&#x02010;time PCR</title><p>Total RNA of MSCs was extracted at the indicated time points with TRIzol Reagent (Invitrogen, Carlsbad, CA). Synthesis of complementary DNA (cDNA) from mRNA was performed via reverse transcription with an iScript cDNA synthesis kit (cat. no. 170&#x02010;8890; Bio&#x02010;Rad). qPCR was conducted in triplicate using SYBR Green Supermix (cat. no. 172&#x02010;5271; Bio&#x02010;Rad). GAPDH was utilized an internal control. The primer sequences are listed in Table <xref rid="jcp29176-tbl-0001" ref-type="table">1</xref>.</p><table-wrap id="jcp29176-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Primer pairs used for PCR</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th valign="bottom" rowspan="1" colspan="1">Gene</th><th valign="bottom" rowspan="1" colspan="1">Sequence</th></tr></thead><tbody valign="top"><tr><td valign="top" rowspan="1" colspan="1">
<italic>GAPDH</italic>
</td><td valign="top" rowspan="1" colspan="1">Fw 5&#x02032;&#x02010;AGGTCGGTGTGAACGGATTTG&#x02010;3&#x02032;</td></tr><tr><td valign="top" rowspan="1" colspan="1"/><td valign="top" rowspan="1" colspan="1">Rv 5&#x02032;&#x02010;TGTAGACCATGTAGTTGAGGTCA&#x02010;3&#x02032;</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<italic>TNF&#x02010;&#x003b1;</italic>
</td><td valign="top" rowspan="1" colspan="1">Fw 5&#x02032;&#x02010;CTATGGCCCAGACCCTCACA&#x02010;3&#x02032;</td></tr><tr><td valign="top" rowspan="1" colspan="1"/><td valign="top" rowspan="1" colspan="1">Rv 5&#x02032;&#x02010;TTGAGATCCATGCCGTTGGC&#x02010;3&#x02032;</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<italic>IFN&#x02010;&#x003b3;</italic>
</td><td valign="top" rowspan="1" colspan="1">Fw 5&#x02032;&#x02010;GCGCCAAGCATTCAATGAGC&#x02010;3&#x02032;</td></tr><tr><td valign="top" rowspan="1" colspan="1"/><td valign="top" rowspan="1" colspan="1">Rv 5&#x02032;&#x02010;CAGCGACTCCTTTTCCGCTT&#x02010;3&#x02032;</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<italic>TGF&#x02010;&#x003b2;1</italic>
</td><td valign="top" rowspan="1" colspan="1">Fw 5&#x02032;&#x02010;TTCAGCGCTCACTGCTCTTG&#x02010;3&#x02032;</td></tr><tr><td valign="top" rowspan="1" colspan="1"/><td valign="top" rowspan="1" colspan="1">Rv 5&#x02032;&#x02010;TTGGTATCCAGGGCTCTCCG&#x02010;3&#x02032;</td></tr><tr><td valign="top" rowspan="1" colspan="1">
<italic>Becn1</italic>
</td><td valign="top" rowspan="1" colspan="1">Fw 5&#x02032;&#x02010;AGGCGAAACCAGGAGAGAC&#x02010;3&#x02032;</td></tr><tr><td valign="top" rowspan="1" colspan="1"/><td valign="top" rowspan="1" colspan="1">Rv 5&#x02032;&#x02010;CCTCCCCGATCAGAGTGAA&#x02010;3&#x02032;</td></tr></tbody></table><table-wrap-foot><fn id="jcp29176-tbl1-note-0001"><p>Abbreviations: Fw, forward primer; PCR, polymerase chain reaction; Rv, reverse primer.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="jcp29176-sec-0160"><label>2.14</label><title>Statistical analysis</title><p>All data are expressed as means&#x02009;&#x000b1;&#x02009;<italic>SEM</italic>s, and were statistically analyzed using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA). Means of two groups were compared by Student's <italic>t</italic> tests. For multiple comparisons, statistical analysis was performed by analysis of variance. A <italic>p</italic>&#x02009;&#x0003c;&#x02009;.05 was considered statistically significant.</p></sec></sec><sec id="jcp29176-sec-0170"><label>3</label><title>RESULTS</title><sec id="jcp29176-sec-0180"><label>3.1</label><title>Autophagy of MSCs occurred in a LF microenvironment</title><p>To determine whether autophagy of MSCs occurred during LF, EGFP&#x02010;control lentivirus&#x02010;transfected MSCs (shNC&#x02010;MSCs) were transfused into oil mice or CCl<sub>4</sub> mice via the tail vein. Interestingly, the number of EGFP<sup>+</sup> MSCs and the extent of MAP1LC3 puncta in the MSCs were increased in CCl<sub>4</sub> mice, but not in oil mice at 72&#x02009;hr following cell administration (Figure <xref rid="jcp29176-fig-0001" ref-type="fig">1</xref>a).</p><fig fig-type="Figure" xml:lang="en" id="jcp29176-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Autophagy of mesenchymal stem cells (MSCs) occurred under liver fibrosis microenvironment. (a) MSCs were transfused into oil mice and CCl<sub>4</sub> mice via tail vein at 5 weeks following oil or CCl<sub>4</sub> administration. Mice were euthanized at 0 and 72&#x02009;hr after cell administration, and livers were cut into frozen sections. Sections were incubated with anti&#x02010;MAP1LC3&#x02010;A/B antibodies and DAPI and visualized under a fluorescent microscope. (b) Western blot analysis of MAP1LC3&#x02010;I/MAP1LC3&#x02010;II expression in MSCs starved or stimulated with tumor necrosis factor&#x02010;&#x003b1; (TNF&#x02010;&#x003b1;), interferon&#x02010;&#x003b3; (IFN&#x02010;&#x003b3;), or transforming growth factor&#x02010;&#x003b2;1 (TGF&#x02010;&#x003b2;1) for 0&#x02013;24&#x02009;hr. The blots shown are representative of three independent experiments. (c) The MSCs were starved, not starved (control), or stimulated with TNF&#x02010;&#x003b1;, IFN&#x02010;&#x003b3;, and TGF&#x02010;&#x003b2;1 for 6&#x02009;hr. Autophagosomes in MSCs were visualized using transmission electron microscopy. Representative images of three independent experiments are presented. AV, autophagic vacuoles; N, nucleus. (d, e) Immunofluorescence staining of MAP1LC3 in MSCs starved, not starved (control), or primed with TNF&#x02010;&#x003b1;, IFN&#x02010;&#x003b3;, and TGF&#x02010;&#x003b2;1 alone or in varied combinations for 6&#x02009;hr. The representative images from three independent experiments are shown. The MSCs presented with MAP1LC3 dots were numbered for five images from each group. (f) <italic>Becn1</italic> messenger RNA (mRNA) expression in MSCs stimulated without or with TNF&#x02010;&#x003b1;, IFN&#x02010;&#x003b3;, or TGF&#x02010;&#x003b2;1 alone or in varied combinations were detected using quantitative polymerase chain reaction (qPCR). (g) Western blot analysis showing MAP1LC3&#x02010;I, MAP1LC3&#x02010;II, and p62 expression in MSCs stimulated with TNF&#x02010;&#x003b1;, IFN&#x02010;&#x003b3;, and TGF&#x02010;&#x003b2;1 alone or in varied synergies for 6&#x02009;hr. Representative data from three experiments are shown. (h) shNC&#x02010;MSCs and sh<italic>Becn1</italic>&#x02010;MSCs were cultivated in absence or presence of TNF&#x02010;&#x003b1;, IFN&#x02010;&#x003b3;, and TGF&#x02010;&#x003b2;1. <italic>Becn1</italic> mRNA expression was measured using qPCR. (i) The protein expression levels of MAP1LC3&#x02010;I, MAP1LC3&#x02010;II, BECN1, and p62 were detected using western blot analysis. Data are presented as means&#x02009;&#x000b1;&#x02009;<italic>SEM</italic>s. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;.05, **<italic>p&#x02009;</italic>&#x0003c;<italic>&#x02009;</italic>.01, ***<italic>p&#x02009;</italic>&#x0003c;<italic>&#x02009;</italic>.001. In all cases the concentrations used for treatments were as follows: TNF&#x02010;&#x003b1; (20&#x02009;ng/ml), IFN&#x02010;&#x003b3; (50&#x02009;ng/ml), and TGF&#x02010;&#x003b2;1 (10&#x02009;ng/ml). DAPI, 4&#x02032;,6&#x02010;diamidino&#x02010;2&#x02010;phenylindole [Color figure can be viewed at wileyonlinelibrary.com]</p></caption><graphic id="nlm-graphic-3" xlink:href="JCP-235-2722-g001"/></fig><p>MSCs were cultivated with or without TNF&#x02010;&#x003b1;, IFN&#x02010;&#x003b3;, and TGF&#x02010;&#x003b2;1, and autophagy activation in MSCs was analyzed. Cells that underwent starvation served as positive controls. Significant increases in the MAP1LC3&#x02010;II/MAP1LC3&#x02010;I ratio were observed in MSCs stimulated with TNF&#x02010;&#x003b1;, IFN&#x02010;&#x003b3;, or TGF&#x02010;&#x003b2;1 for different time points, with the most obvious elevation occurring at 6&#x02009;hr (Figure <xref rid="jcp29176-fig-0001" ref-type="fig">1</xref>b). Furthermore, we found that among the three LF&#x02010;related cytokines, IFN&#x02010;&#x003b3; treatment induced marked elevation in autophagosome formation in MSCs, as observed by transmission electron microscopy (Figure <xref rid="jcp29176-fig-0001" ref-type="fig">1</xref>c) and fluorescence microscopy (Figure <xref rid="jcp29176-fig-0001" ref-type="fig">1</xref>d,e).</p></sec><sec id="jcp29176-sec-0190"><label>3.2</label><title>LF&#x02010;related cytokines triggered autophagy in MSCs via upregulation of BECN1</title><p>To determine whether the autophagy activated by LF&#x02010;related cytokines was triggered by upregulating BECN1, MSCs were stimulated with the three cytokines alone or in different combinations for 6&#x02009;hr. All treatments significantly upregulated mRNA and protein expression of BECN1 (Figure <xref rid="jcp29176-fig-0001" ref-type="fig">1</xref>f,g) downregulated p62 protein expression (Figure <xref rid="jcp29176-fig-0001" ref-type="fig">1</xref>g).</p><p>To further explore the function that BECN1 played in autophagy, lentivirus&#x02010;expressing shRNA specific to <italic>Becn1</italic> (sh<italic>Becn1</italic>&#x02010;MSCs) was used to downregulate BECN1 expression in MSCs. Subsequently, the cells were cultivated with or without TNF&#x02010;&#x003b1;, IFN&#x02010;&#x003b3;, and TGF&#x02010;&#x003b2;1. For the control group, MSCs were transfected with a lentivirus&#x02010;expressing scrambled shRNA (shNC&#x02010;MSCs). We revealed that <italic>Becn1</italic> knockdown reduced the MAP1LC3&#x02010;II/MAP1LC3&#x02010;I ratio and increased p62 expression levels after treatment with or without the three LF&#x02010;related cytokines compared with that in the control shRNA&#x02010;MSCs (Figure <xref rid="jcp29176-fig-0001" ref-type="fig">1</xref>h,i). These findings suggested that treatment with the three LF&#x02010;related cytokines triggered autophagy in MSCs by upregulation of BECN1.</p></sec><sec id="jcp29176-sec-0200"><label>3.3</label><title>Knockdown of <italic>Becn1</italic> promoted the antifibrotic efficacy of MSCs in CCl<sub>4</sub>&#x02010;induced LF</title><p>To explore whether autophagy inhibition by <italic>Becn1</italic> knockdown affected the therapeutic capacity of MSCs in LF, shNC&#x02010;MSCs and sh<italic>Becn1</italic>&#x02010;MSCs were injected weekly into mice via the tail vein from Weeks 3 to 5. After 5 weeks, the extent of LF was evaluated via histopathological analyses. Gross examination showed that livers of mice in the CCl<sub>4</sub>&#x02009;+&#x02009;sh<italic>Becn1</italic> group were smoother and softer than those of mice in the CCl<sub>4</sub>&#x02009;+&#x02009;PBS and CCl<sub>4</sub>&#x02009;+&#x02009;shNC groups. The hepatic pathological changes were significantly ameliorated in the sh<italic>Becn1</italic>&#x02010;MSC&#x02010;treated group in contrast to those in the CCl<sub>4</sub>&#x02009;+&#x02009;PBS and CCl<sub>4</sub>&#x02009;+&#x02009;shNC groups (Figure <xref rid="jcp29176-fig-0002" ref-type="fig">2</xref>a). Moreover, HE, Masson, and Sirius red staining all indicated that transplantation of sh<italic>Becn1</italic>&#x02010;MSCs markedly ameliorated LF, as indicated by reduced collagen deposition, smaller fibrotic areas, and decreased inflammatory cell infiltration as compared to those observed in the CCl<sub>4</sub>&#x02009;+&#x02009;PBS and CCl<sub>4</sub>&#x02009;+&#x02009;shNC groups (Figure <xref rid="jcp29176-fig-0002" ref-type="fig">2</xref>a).</p><fig fig-type="Figure" xml:lang="en" id="jcp29176-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>
<italic>Becn1</italic> knockdown promoted the antifibrotic efficacy of mesenchymal stem cells in CCl<sub>4</sub>&#x02010;induced liver fibrosis. (a) Mice were randomly selected and designated as the oil&#x02009;+&#x02009;PBS, CCl<sub>4&#x02009;</sub>+<sub>&#x02009;</sub>PBS, CCl<sub>4</sub>&#x02009;+&#x02009;shNC, and CCl<sub>4</sub>&#x02009;+&#x02009;sh<italic>Becn1</italic> groups (<italic>n</italic>&#x02009;=&#x02009;8). Mice were euthanized 3 days after cell transplantation, and pathological alterations in the liver were detected by gross examination, Sirius red staining, Masson staining, and HE staining. Quantification of fibrosis was analyzed, and representative microscopy images are presented. (b) Western blot analysis of &#x003b1;&#x02010;SMA in livers subjected to the indicated treatments. (c) The levels of hydroxyproline were detected in livers subjected to different treatments. (d) Serum concentrations of AST and ALT were determined to indicate the extent of liver parenchyma damage caused by CCl<sub>4</sub> administration. Scale bar, 200&#x02009;&#x003bc;m. The results are presented as means&#x02009;&#x000b1;&#x02009;<italic>SEM</italic>s. ALT, alanine aminotransferase; AST, aspartate aminotransferase; HE,&#x000a0;hematoxylin and eosin; PBS, phosphate&#x02010;buffered saline;&#x000a0;&#x003b1;&#x02010;SMA, &#x003b1;&#x02010;smooth muscle actin. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;.05, **<italic>p&#x02009;&#x0003c;&#x02009;</italic>.01, ***<italic>p&#x02009;</italic>&#x0003c;&#x02009;.001 [Color figure can be viewed at wileyonlinelibrary.com]</p></caption><graphic id="nlm-graphic-5" xlink:href="JCP-235-2722-g002"/></fig><p>&#x003b1;&#x02010;SMA is a biomarker of myofibroblasts, and hydroxyproline levels in liver reflect the severity of LF. Therefore, &#x003b1;&#x02010;SMA expression and hydroxyproline levels in liver were detected, and the results indicated that administration of sh<italic>Becn1</italic>&#x02010;MSCs reduced &#x003b1;&#x02010;SMA expression and hydroxyproline levels in fibrotic livers as compared with those in CCl<sub>4</sub>&#x02009;+&#x02009;PBS and CCl<sub>4</sub>&#x02009;+&#x02009;shNC groups (Figure <xref rid="jcp29176-fig-0002" ref-type="fig">2</xref>b,c). Furthermore, reduced AST and ALT levels were observed in fibrotic livers of mice treated with sh<italic>Becn1</italic>&#x02010;MSCs compared with those in mice in the CCl<sub>4</sub>&#x02009;+&#x02009;PBS and CCl<sub>4</sub>&#x02009;+&#x02009;shNC groups (Figure <xref rid="jcp29176-fig-0002" ref-type="fig">2</xref>d). Taken together, these results confirmed that autophagy inhibition primed by <italic>Becn1</italic> stable knockdown in MSCs could increase their antifibrotic efficacy in LF.</p></sec><sec id="jcp29176-sec-0210"><label>3.4</label><title>sh<italic>Becn1</italic>&#x02010;MSCs inhibited HSCs and Gli1<sup>+</sup> cell proliferation and decreased procollagen I &#x003b1;1 secretion in HSCs</title><p>HSCs activation and proliferation are essential in the hepatic response to injury and liver fibrogenesis. In this study, an in vitro coculture system of HSCs and MSCs was used to further verify the mechanisms through which sh<italic>Becn1</italic>&#x02010;MSCs ameliorate LF. The effects of shNC&#x02010;MSCs and sh<italic>Becn1</italic>&#x02010;MSCs on HSCs proliferation were evaluated following a coculture of 24, 48, and 72&#x02009;hr. Significant decreases in the numbers of HSCs were noted 48 and 72&#x02009;hr after coculture (Figure <xref rid="jcp29176-fig-0003" ref-type="fig">3</xref>a). Furthermore, analysis of the effects of shNC&#x02010;MSCs and sh<italic>Becn1</italic>&#x02010;MSCs on procollagen I &#x003b1;1 secretion from HSCs showed that there was a significant decrease in procollagen I &#x003b1;1 secretion in the sh<italic>Becn1</italic>&#x02010;MSC group after 72&#x02009;hr of coculture compared with that in the control and shNC&#x02010;MSC groups (Figure <xref rid="jcp29176-fig-0003" ref-type="fig">3</xref>b). Because HSCs are the predominant origin of myofibroblasts progenitors and <italic>Gli1</italic> is an in vivo marker of myofibroblast progenitors (Kramann et al., <xref rid="jcp29176-bib-0021" ref-type="ref">2015</xref>), <italic>Gli1</italic> genetic lineage&#x02010;tracing mice were utilized to detect the impact of sh<italic>Becn1</italic>&#x02010;MSCs on Gli1<sup>+</sup> cells in the fibrotic liver in vivo. Our results showed that Gli1<sup>+</sup> cells in fibrotic livers were significantly reduced after transplantation of sh<italic>Becn1</italic>&#x02010;MSCs (Figure <xref rid="jcp29176-fig-0003" ref-type="fig">3</xref>c,d). These results unveiled that the promoted antifibrotic capability of sh<italic>Becn1</italic>&#x02010;MSCs in LF might be attributed to their inhibitory effects on HSCs proliferation.</p><fig fig-type="Figure" xml:lang="en" id="jcp29176-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>sh<italic>Becn1</italic>&#x02010;MSCs inhibited HSCs and Gli1<sup>+</sup> cell proliferation and decreased procollagen I &#x003b1;1 secretion in HSCs. (a) Effects of MSCs on HSCs proliferation were examined using CCK&#x02010;8 assays in the coculture system with PBS, shNC&#x02010;MSCs, or sh<italic>Becn1</italic>&#x02010;MSCs for the indicated times. (b) After coculturing with PBS, shNC&#x02010;MSCs, or sh<italic>Becn1</italic>&#x02010;MSCs for 72&#x02009;hr, HSCs were collected for detection of procollagen type I &#x003b1;1 secretion using enzyme&#x02010;linked immunosorbent assay (<italic>n</italic>&#x02009;=&#x02009;4). (c) To trace <italic>Gli1</italic>
<sup>+</sup> cells in vivo, <italic>Gli1</italic>&#x02010;CreERt2;<italic>tdTomato</italic> genetic lineage&#x02010;tracing mice underwent three intraperitoneal injections of tamoxifen (3&#x02009;&#x000d7;&#x02009;0.1&#x02009;mg/kg) every other day at 14 days before LF induction. Mice LF model was established via intraperitoneal injection of CCl<sub>4</sub> olive oil solution (CCl<sub>4</sub>:olive oil&#x02009;=&#x02009;1:3) twice per week for 5 consecutive weeks. MSCs or PBS were administered into mice weekly from Weeks 3 to 5 via the tail vein. (d) Mice were divided into the oil&#x02009;+&#x02009;PBS, CCl<sub>4&#x02009;</sub>+<sub>&#x02009;</sub>PBS, CCl<sub>4&#x02009;</sub>+<sub>&#x02009;</sub>shNC, and CCl<sub>4&#x02009;</sub>+<sub>&#x02009;</sub>sh<italic>Becn1</italic> groups (<italic>n</italic>&#x02009;=&#x02009;8) and were euthanized 3 days after cell administration. Frozen sections of the liver was stained with anti&#x02010;&#x003b1;&#x02010;SMA antibodies and counterstained with DAPI. The observation of tdTomato expression was carried out under a fluorescent microscope. Scale bar, 200&#x02009;&#x003bc;m. Data are presented as means&#x02009;&#x000b1;&#x02009;<italic>SEM</italic>s. HSCs, hepatic stellate cells; LF, liver fibrosis; MSCs, mesenchymal stem cell; PBS, phosphate&#x02010;buffered saline; &#x003b1;&#x02010;SMA, &#x003b1;&#x02010;smooth muscle actin. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;.05, **<italic>p&#x02009;&#x0003c;&#x02009;</italic>.01, ***<italic>p&#x02009;&#x0003c;&#x02009;</italic>.001 [Color figure can be viewed at wileyonlinelibrary.com]</p></caption><graphic id="nlm-graphic-7" xlink:href="JCP-235-2722-g003"/></fig></sec><sec id="jcp29176-sec-0220"><label>3.5</label><title>sh<italic>Becn1</italic>&#x02010;MSCs attenuated infiltration of CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes in CCl<sub>4</sub>&#x02010;induced fibrotic livers</title><p>The involvement of CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocyte infiltration in LF has been confirmed (Pesce et al., <xref rid="jcp29176-bib-0030" ref-type="ref">2006</xref>; Wynn, <xref rid="jcp29176-bib-0047" ref-type="ref">2004</xref>). Therefore, changes in T lymphocyte populations in the liver upon MSC treatment were further investigated to determine the mechanisms through which sh<italic>Becn1</italic>&#x02010;MSCs alleviated LF. Fluorescence microscopy results demonstrated that the numbers of CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes were increased in CCl<sub>4</sub>&#x02010;induced fibrotic livers. Notably, sh<italic>Becn1&#x02010;</italic>MSCs substantially lowered the numbers of CD4<sup>+</sup> and CD8<sup>+</sup> T cells infiltrating the CCl<sub>4</sub>&#x02010;induced fibrotic livers compared with that in the shNC&#x02010;MSC group (Figure <xref rid="jcp29176-fig-0004" ref-type="fig">4</xref>a,b). Indeed, our findings showed that BECN1 downregulation in MSCs triggered a decrease in the absolute numbers of CD4<sup>+</sup> and CD8<sup>+</sup> lymphocytes in CCl<sub>4</sub>&#x02010;induced fibrotic livers. Thus, these observations suggested that autophagy suppression in MSCs modulated by <italic>Becn1</italic> stable knockdown could suppress T&#x02010;cell infiltration in the fibrotic liver, indicating that the decreased CD4<sup>+</sup> and CD8<sup>+</sup> T&#x02010;cell infiltration accounted for the strengthened antifibrotic effects of sh<italic>Becn1</italic>&#x02010;MSCs in CCl<sub>4</sub>&#x02010;induced LF mice.</p><fig fig-type="Figure" xml:lang="en" id="jcp29176-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Accumulation of CD4<sup>+</sup> and CD8<sup>+</sup> lymphocytes in fibrotic livers was substantially attenuated in sh<italic>Becn1</italic>&#x02010;MSC&#x02010;treated CCl<sub>4</sub> mice. (a) Mice were euthanized 3 days after cell transplantation. Livers were resected from oil mice and CCl<sub>4</sub> mice treated with PBS, shNC&#x02010;MSC, or sh<italic>Becn1</italic>&#x02010;MSC followed by OCT embedding. Frozen sections were incubated with CD4 and CD8 primary antibodies and observed under a fluorescent microscope. Representative figures are presented. Scale bars, 50&#x02009;&#x003bc;m. (b) Quantitative analysis of CD4<sup>+</sup> and CD8<sup>+</sup> lymphocytes numbers was performed in a &#x000d7;400&#x02009;hpf. The findings are expressed as means&#x02009;&#x000b1;&#x02009;<italic>SEM</italic>s. MSC, mesenchymal stem cell; PBS, phosphate&#x02010;buffered saline. **<italic>p&#x02009;&#x0003c;&#x02009;</italic>.01, ***<italic>p&#x02009;</italic>&#x0003c;&#x02009;.001 [Color figure can be viewed at wileyonlinelibrary.com]</p></caption><graphic id="nlm-graphic-9" xlink:href="JCP-235-2722-g004"/></fig></sec><sec id="jcp29176-sec-0230"><label>3.6</label><title>Chemotaxis of exogenous MSCs into fibrotic livers and colocalization of exogenous MSCs, Gli1<sup>+</sup> cells, and T cells in LF</title><p>shNC&#x02010;MSCs&#x000a0;and sh<italic>Becn1</italic>&#x02010;MSCs were administered into oil or CCl<sub>4</sub> mice, and the localization of MSCs was detected at 3 days after cell transplantation under a fluorescence microscope. Notably, transplanted shNC&#x02010;MSCs and sh<italic>Becn1</italic>&#x02010;MSCs were recruited to CCl<sub>4</sub>&#x02010;induced fibrotic livers, as demonstrated by significant increases in the numbers of EGFP<sup>+</sup> cells located in CCl<sub>4</sub>&#x02010;induced fibrotic livers; few EGFP<sup>+</sup> cells were found in normal livers (Figure <xref rid="jcp29176-fig-0005" ref-type="fig">5</xref>a). In addition, immunofluorescence staining for &#x003b1;&#x02010;SMA demonstrated the colocalization of exogenous MSCs and fiber collagen accumulation in fibrotic livers (Figure <xref rid="jcp29176-fig-0005" ref-type="fig">5</xref>b).</p><fig fig-type="Figure" xml:lang="en" id="jcp29176-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Chemotaxis of exogenous mesenchymal stem cell (MSCs) into fibrotic livers and colocalization of exogenous MSCs, T cells, and Gli1<sup>+</sup> cells in liver fibrosis (LF). (a) Oil and CCl<sub>4</sub> mice treated with shNC&#x02010;MSCs or sh<italic>Becn1</italic>&#x02010;MSCs (on Week 5) were killed 3 days after cell transplantation. MSCs in the liver were visualized under a fluorescent microscope. The numbers of MSCs in the liver were measured in &#x000d7;50&#x02009;&#x02009;hpf. Representative images are presented. The findings are expressed as means&#x02009;&#x000b1;&#x02009;<italic>SEM</italic>s. ***<italic>p&#x02009;</italic>&#x0003c;&#x02009;.001. (b) CCl<sub>4</sub> mice were treated with shNC&#x02010;MSCs and killed 3 days after cell transplantation. Liver sections from these mice were incubated with anti&#x02010;&#x003b1;&#x02010;SMA antibodies, and sections were visualized under a fluorescent microscope. Representative images are shown. (c) CCl<sub>4</sub> mice were killed, and frozen sections of liver sections were incubated with CD4, CD8, and &#x003b1;&#x02010;SMA primary antibodies. CD4<sup>+</sup> and CD8<sup>+</sup> lymphocytes and &#x003b1;&#x02010;SMA<sup>+</sup> cells were visualized under a fluorescent microscope. (d) The LF model was built by CCl<sub>4</sub> injection using <italic>Gli1</italic>&#x02010;CreERt2;td<italic>Tomato</italic> genetic lineage&#x02010;tracing mice. Liver sections were incubated with anti&#x02010;&#x003b1;&#x02010;SMA antibody. The &#x003b1;&#x02010;SMA<sup>+</sup> and Gli1<sup>+</sup> cells were examined using fluorescent microscopy. Scale bars, 500&#x02009;&#x003bc;m. &#x003b1;&#x02010;SMA, &#x003b1;&#x02010;smooth muscle actin [Color figure can be viewed at wileyonlinelibrary.com]</p></caption><graphic id="nlm-graphic-11" xlink:href="JCP-235-2722-g005"/></fig><p>Immunofluorescence staining was then conducted for evaluating the distributions of CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes in CCl<sub>4</sub>&#x02010;induced fibrotic livers. In addition, <italic>Gli1</italic>&#x02010;CreERt2;<italic>tdTomato</italic> genetic lineage&#x02010;tracing mice were utilized to assess the distribution of Gli1<sup>+</sup> cells in CCl<sub>4</sub>&#x02010;induced fibrotic livers. Notably, immunofluorescence staining demonstrated that CD4<sup>+</sup> and CD8<sup>+</sup> T cells and Gli1<sup>+</sup> cells were all mainly deposited in the &#x003b1;&#x02010;SMA<sup>+</sup> portal area, suggesting the colocalization of the three cell types within the fibrotic portal area in CCl<sub>4</sub>&#x02010;induced fibrotic livers (Figure <xref rid="jcp29176-fig-0005" ref-type="fig">5</xref>c,d). These findings provided direct evidence for colocalization of the transplanted MSCs, Gli1<sup>+</sup> cells, and CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes in the portal fibrotic area in CCl<sub>4</sub>&#x02010;induced fibrotic livers.</p></sec><sec id="jcp29176-sec-0240"><label>3.7</label><title>Knockdown of <italic>Becn1</italic> suppressed autophagy and promoted the expression of PTGS2/PGE<sub>2</sub> in MSCs</title><p>Next, we explored the mechanisms delineating the increased antifibrotic efficacy of sh<italic>Becn1</italic>&#x02010;MSCs in fibrotic livers. shNC&#x02010;MSCs and sh<italic>Becn1</italic>&#x02010;MSCs were administered intravenously into CCl<sub>4</sub> mice, and autophagy activity of MSCs was detected. A significant decrease in MAP1LC3 dot formation was observed in sh<italic>Becn1</italic>&#x02010;MSCs compared with that in shNC&#x02010;MSCs (Figure <xref rid="jcp29176-fig-0006" ref-type="fig">6</xref>a). We confirmed that the liver fibrotic microenvironment induced autophagy in MSCs. Therefore, the impact of <italic>Becn1</italic> knockdown on autophagic activity in MSCs was determined. MSCs were treated with inflammatory cytokines in presence or absence of the classical autophagy inhibitor 3&#x02010;MA or the well&#x02010;characterized autophagy inducer rapamycin, and MAP1LC3&#x02010;I, MAP1LC3&#x02010;II, and p62 expression levels were assayed. In the sh<italic>Becn1</italic>&#x02010;MSC group treated with the three LF&#x02010;related cytokines, reduced MAP1LC3&#x02010;II/MAP1LC3&#x02010;I ratios, but elevated PTGS2 expression were observed compared with those in the shNC&#x02010;MSC group; however, rapamycin treatment abrogated the effects of sh<italic>Becn1</italic>&#x02010;MSCs (Figure <xref rid="jcp29176-fig-0006" ref-type="fig">6</xref>b). Similarly, 3&#x02010;MA treatment decreased the MAP1LC3&#x02010;II/MAP1LC3&#x02010;I ratio and upregulated p62 expression in shNC&#x02010;MSCs treated with the three LF&#x02010;related cytokines (Figure <xref rid="jcp29176-fig-0006" ref-type="fig">6</xref>b). In addition, secretion of PGE<sub>2</sub>, a downstream product of PTGS2 and an effector of immunosuppression, in MSCs treated with the three LF&#x02010;related cytokines was markedly elevated in the supernatant fraction of sh<italic>Becn1</italic>&#x02010;MSCs compared with that of shNC&#x02010;MSCs (Figure <xref rid="jcp29176-fig-0006" ref-type="fig">6</xref>c). The elevation of PGE<sub>2</sub> was also observed in the sera of sh<italic>Becn1</italic>&#x02010;MSC&#x02010;treated mice with LF compared with that in mice treated with shNC&#x02010;MSCs or PBS (Figure <xref rid="jcp29176-fig-0006" ref-type="fig">6</xref>d). The mRNA expression levels of key LF&#x02010;related cytokines were markedly decreased in LF and in the sera of sh<italic>Becn1</italic>&#x02010;MSC&#x02010;treated mice with LF as compared with those in mice treated with shNC&#x02010;MSCs (Figure <xref rid="jcp29176-fig-0006" ref-type="fig">6</xref>e,f). These results indicated that sh<italic>Becn1</italic>&#x02010;MSCs potentiated the antifibrotic efficacy of MSCs by suppressing inflammation&#x02010;induced autophagy and generating more PGE<sub>2</sub>.</p><fig fig-type="Figure" xml:lang="en" id="jcp29176-fig-0006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Knockdown of <italic>Becn1</italic> suppressed inflammation&#x02010;induced autophagy and generated more PTGS2/PGE<sub>2</sub> in mesenchymal stem cells (MSCs). (a) shNC&#x02010;MSCs and sh<italic>Becn1</italic>&#x02010;MSCs were injected into liver fibrosis model mice, which were euthanized 3 days posterior to cell infusion. Frozen sections of liver tissues were stained with anti&#x02010;MAP1LC3&#x02010;A/B antibodies with nuclei counterstained with DAPI and visualized under a fluorescent microscopy. (b) The expression levels of PTGS2, p62, MAP1LC3&#x02010;I, and MAP1LC3&#x02010;II in MSCs were determined by western blot analysis analysis. shNC&#x02010;MSCs were incubated in presence or absence of 3&#x02010;MA, and sh<italic>Becn1</italic>&#x02010;MSCs were incubated in presence or absence of rapamycin, under combined stimulation with tumor necrosis factor&#x02010;&#x003b1; (TNF&#x02010;&#x003b1;, 20&#x02009;ng/ml), interferon&#x02010;&#x003b3; (IFN&#x02010;&#x003b3;, 50&#x02009;ng/ml), and transforming growth factor&#x02010;&#x003b2;1 (TGF&#x02010;&#x003b2;1, 10&#x02009;ng/ml) for 12&#x02009;hr. (c) shNC&#x02010;MSCs and sh<italic>Becn1</italic>&#x02010;MSCs underwent single or combined treatment with TNF&#x02010;&#x003b1; (20&#x02009;ng/ml), IFN&#x02010;&#x003b3; (50&#x02009;ng/ml), or TGF&#x02010;&#x003b2;1 (10&#x02009;ng/ml) for 24&#x02009;hr, and PGE<sub>2</sub> secretion in the supernatant was assayed using enzyme&#x02010;linked immunosorbent assay (ELISA). The results are presented as means&#x02009;&#x000b1;&#x02009;<italic>SEM</italic>s. (d) Mice were divided into the oil&#x02009;+&#x02009;PBS, CCl<sub>4&#x02009;+&#x02009;</sub>PBS, CCl<sub>4&#x02009;+&#x02009;</sub>shNC, and CCl<sub>4&#x02009;+&#x02009;</sub>sh<italic>Becn1</italic> groups and euthanized. Subsequently, serum levels of PGE<sub>2</sub> were quantified using ELISA, and (e) <italic>TNF&#x02010;&#x003b1;, IFN&#x02010;&#x003b3;</italic>, and <italic>TGF&#x02010;&#x003b2;1</italic> messenger RNA expression in the mice liver were measured by quantitative polymerase chain reaction. (f) Serum concentrations of TNF&#x02010;&#x003b1;, IFN&#x02010;&#x003b3;, and TGF&#x02010;&#x003b2;1 were determined using ELISA. The findings are expressed as means&#x02009;&#x000b1;&#x02009;<italic>SEM</italic>s. PGE<sub>2</sub>,&#x000a0;prostaglandin E<sub>2</sub>; PTGS2, prostaglandin&#x02010;endoperoxide synthase 2. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;.05, **<italic>p&#x02009;</italic>&#x0003c;&#x02009;.01, ***<italic>p&#x02009;&#x0003c;&#x02009;</italic>.001 [Color figure can be viewed at wileyonlinelibrary.com]</p></caption><graphic id="nlm-graphic-13" xlink:href="JCP-235-2722-g006"/></fig></sec></sec><sec id="jcp29176-sec-0250"><label>4</label><title>DISCUSSION</title><p>Although the potent immunosuppressive function of MSCs renders them attractive candidates for antifibrotic treatments, the consequent responses of MSCs under hepatic context following transplantation needs to be further elucidated, as their therapeutic efficacy is inconsistent (Alfaifi, Eom, Newsome, &#x00026; Baik, <xref rid="jcp29176-bib-0002" ref-type="ref">2018</xref>; Consentius, Reinke, &#x00026; Volk, <xref rid="jcp29176-bib-0008" ref-type="ref">2015</xref>). The inconsistent findings gained from different studies are attributable to the different sources and lack of control over the cell fate of the transplanted MSCs in vivo. Therefore, determining mechanisms through which the LF microenvironment controls the immunoregulatory functions of MSCs and the fate of MSCs is expected to deliver new insights into improving the efficacy of MSC&#x02010;based immunotherapy.</p><p>In this study, we revealed that autophagy occurred in MSCs due to reaction with the LF microenvironment. Indeed, the LF microenvironment suppressed the treatment efficacy of the transplanted MSCs via autophagy induction. Nevertheless, counteracting LF microenvironment&#x02010;induced autophagy by <italic>Becn1</italic> knockdown significantly promoted the antifibrotic effects of MSCs. The improved antifibrotic potential of sh<italic>Becn1</italic>&#x02010;MSCs may be attributable to their improved suppression of CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocyte accumulation and HSCs and Gli1<sup>+</sup> cell proliferation. Furthermore, we found that <italic>Becn1</italic> knockdown in MSCs altered PTGS2/PGE<sub>2</sub> secretion, resulting in potent immunoregulatory effects. These findings suggested that autophagy regulation in MSCs might serve as a promising remedy to improve the antifibrotic efficacy of MSCs on LF and other inflammatory disorders.</p><p>Recent studies have shown that the results of MSC&#x02010;based therapies are determined by the interplay between MSCs and the inflammatory microenvironment (Mougiakakos et al., <xref rid="jcp29176-bib-0028" ref-type="ref">2011</xref>; Ren et al., <xref rid="jcp29176-bib-0034" ref-type="ref">2008</xref>). For example, studies performed by Shi et al. (<xref rid="jcp29176-bib-0038" ref-type="ref">2010</xref>) indicated that TNF&#x02010;&#x003b1; and IFN&#x02010;&#x003b3; are critical cytokines inducing immunosuppression of MSCs. Interleukin (IL)&#x02010;17 cooperates with IFN&#x02010;&#x003b3; and TNF&#x02010;&#x003b1; to evoke immunoinhibition via boosting expression of inducible nitric oxide synthase in MSCs (Han et al., <xref rid="jcp29176-bib-0017" ref-type="ref">2014</xref>). In the current study, shNC&#x02010;MSCs were transfused into oil mice and CCl<sub>4</sub> mice. Notably, we confirmed that MSCs exhibited autophagy under the context of LF microenvironment in vivo, as demonstrated by marked increases in EGFP<sup>+</sup> MSCs and MAP1LC3 puncta in the MSCs in CCl<sub>4</sub> mice.</p><p>Proinflammatory cytokines, such as TNF&#x02010;&#x003b1; and IFN&#x02010;&#x003b3;, have vital effect on pathogenesis of LF (Seki &#x00026; Schwabe, <xref rid="jcp29176-bib-0037" ref-type="ref">2015</xref>). TGF&#x02010;&#x003b2;1 is a master profibrotic factor and regulator of LF, and blocking TGF&#x02010;&#x003b2;1 signaling pathways decreases fibrogenesis in animal models (Meng, Nikolic&#x02010;Paterson, &#x00026; Lan, <xref rid="jcp29176-bib-0027" ref-type="ref">2016</xref>). TGF&#x02010;&#x003b2;1 induces the production and inhibits the degradation of ECM proteins. Indeed, our results confirmed that TNF&#x02010;&#x003b1;, IFN&#x02010;&#x003b3;, and TGF&#x02010;&#x003b2;1 treatment induced marked increases in autophagosome formation, accompanied by significant increases in the MAP1LC3&#x02010;II/MAP1LC3&#x02010;I ratio. TNF&#x02010;&#x003b1; or IFN&#x02010;&#x003b3; stimulated autophagy in MSCs at about 4&#x02009;hr, while TGF&#x02010;&#x003b2;1 induced increased autophagy in MSCs later than TNF&#x02010;&#x003b1; and IFN&#x02010;&#x003b3;. This may be attributed to early inflammatory factors of liver damage such as TNF&#x02010;&#x003b1; and IFN&#x02010;&#x003b3;, which activate immune cells and induce inflammation (Ge, Huang, &#x00026; Yao, <xref rid="jcp29176-bib-0015" ref-type="ref">2018</xref>). TGF&#x02010;&#x003b2;1 is an important profibrotic factor and an immunomodulatory molecule (Fujio et al., <xref rid="jcp29176-bib-0013" ref-type="ref">2016</xref>). Due to the different effects of these factors, there may be differences in the timing of induction of autophagy in MSCs. In vitro studies in MSCs further confirmed the crosstalk between autophagy and the LF microenvironment, consistent with our <italic>i</italic>n vivo findings and with the previous findings demonstrating that TNF&#x02010;&#x003b1; and IFN&#x02010;&#x003b3; could activate autophagy in various cell types (Yuan et al., <xref rid="jcp29176-bib-0048" ref-type="ref">2018</xref>). Moreover, our results were further supported by a study confirming that TGF&#x02010;&#x003b2;1 stimulates autophagy, suggesting that autophagy may participate in fibrosis via the TGF&#x02010;&#x003b2;1 pathway (Ghavami et al., <xref rid="jcp29176-bib-0016" ref-type="ref">2015</xref>). Taken together, these findings suggested that the microenvironment of LF, as defined by chronic inflammatory responses involving the proinflammatory factors TNF&#x02010;&#x003b1; and IFN&#x02010;&#x003b3; and the subsequent repair process regulated by the profibrotic factor TGF&#x02010;&#x003b2;1, triggered autophagy in MSCs both in vivo and in vitro.</p><p>We also found that the three LF&#x02010;related cytokines upregulated both the mRNA and protein expression of BECN1, and downregulated p62 protein expression in MSCs. Consistent with this, <italic>Becn1</italic> knockdown reduced the MAP1LC3&#x02010;II/MAP1LC3&#x02010;I ratio and increased P62 expression in MSCs. These findings suggested that the autophagy triggered by the three LF&#x02010;related cytokines might be attributed to BECN1 upregulation in MSCs, which supported the past research demonstrating that IFN&#x02010;&#x003b3; and TNF&#x02010;&#x003b1; trigger BECN1 expression to induce autophagy (Djavaheri&#x02010;Mergny et al., <xref rid="jcp29176-bib-0012" ref-type="ref">2006</xref>; Tu et al., <xref rid="jcp29176-bib-0044" ref-type="ref">2011</xref>) and that autophagy is inhibited by reducing TGF&#x02010;&#x003b2;1 secretion and TGF&#x02010;&#x003b2;1/Smad signaling (T. Liu et al., <xref rid="jcp29176-bib-0024" ref-type="ref">2018</xref>).</p><p>As an evolutionarily highly conserved cellular process, autophagy functions to maintain intracellular homeostasis (Cadwell, <xref rid="jcp29176-bib-0006" ref-type="ref">2016</xref>). Emerging evidence has shown close crosstalk between autophagy and immunomodulation (Clarke &#x00026; Simon, <xref rid="jcp29176-bib-0007" ref-type="ref">2018</xref>). Moreover, autophagy plays pivotal role in T&#x02010;cell homeostasis and can modulate Th1/Th2 T&#x02010;cell responses (Deretic, <xref rid="jcp29176-bib-0010" ref-type="ref">2012</xref>). In the present study, we revealed the promoted antifibrotic capability of sh<italic>Becn1</italic>&#x02010;MSCs in LF in contrast to that in shNC&#x02010;MSCs. Importantly, proinflammatory cytokines are a prerequisite for MSCs to exert their immune&#x02010;inhibitory functions (Ren et al., <xref rid="jcp29176-bib-0034" ref-type="ref">2008</xref>). Nevertheless, these cytokines may initiate a negative feedback loop to curb the immunosuppressive properties of MSCs by activating autophagy under LF microenvironment. Conversely, inhibiting autophagy by <italic>Becn1</italic> knockdown endowed MSCs with improved antifibrotic properties in CCl<sub>4</sub>&#x02010;induced mice, as demonstrated by decreased collagen deposition, inflammatory cell infiltration, necrotic hepatocytes, and reduced serum concentrations of AST and ALT in the sh<italic>Becn1</italic>&#x02010;MSC group (Dang et al., <xref rid="jcp29176-bib-0009" ref-type="ref">2014</xref>) found that inflammatory condition hampered the immunoinhibitive potential of MSCs by priming autophagy in a mouse model of experimental autoimmune encephalitis, supporting our findings. Similar results indicating protective effect of bone MSCs on <italic>n</italic>&#x02010;hexane&#x02010;induced neuropathy through autophagy inhibition were also found in another study (Hao et al., <xref rid="jcp29176-bib-0018" ref-type="ref">2018</xref>). Collectively, our results demonstrate that counteracting LF microenvironment&#x02010;induced autophagy via stable knockdown of <italic>Becn1</italic> remarkably promotes the antifibrotic effects of MSCs.</p><p>Myofibroblasts derived from HSCs are a potential therapeutic target for antifibrotic therapies (Puche, Saiman, &#x00026; Friedman, <xref rid="jcp29176-bib-0031" ref-type="ref">2013</xref>). Interestingly, a genetic lineage&#x02010;tracing analysis performed by Kramann et al. (<xref rid="jcp29176-bib-0021" ref-type="ref">2015</xref>) strongly suggested that Gli1 is a specific biomarker for myofibroblast progenitors. Our results suggested that sh<italic>Becn1</italic>&#x02010;MSCs inhibited the proliferation of HSCs both in vivo and in vitro and decreased the secretion of procollagen I &#x003b1;1 in HSCs in an in vitro coculture system. These findings affirmed that the inhibitive function on HSCs proliferation might contribute to the augmented therapeutic consequence of sh<italic>Becn1</italic>&#x02010;MSCs in LF.</p><p>The onset and progression of LF are closely related to T&#x02010;cell&#x02010;mediated immune responses (Pesce et al., <xref rid="jcp29176-bib-0030" ref-type="ref">2006</xref>; Wynn, <xref rid="jcp29176-bib-0047" ref-type="ref">2004</xref>), and the regulatory effect of MSCs on T lymphocyte proliferative capability confers them attractive candidates for antifibrotic treatment (Ren et al., <xref rid="jcp29176-bib-0034" ref-type="ref">2008</xref>). Moreover, autophagy is imperative for both survival and immune function of CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes (Jia et al., <xref rid="jcp29176-bib-0020" ref-type="ref">2015</xref>). In this regard, the roles of autophagy played in the immunosuppressive properties of MSCs were exploited. Our results showed that transplanted MSCs were selectively recruited to the fibrotic portal area in the liver. Furthermore, sh<italic>Becn1</italic>&#x02010;MSCs obviously promoted the immunosuppressive capability of MSCs in CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocyte proliferation. This finding suggested that the inhibitive effect of sh<italic>Becn1</italic>&#x02010;MSCs on infiltration of CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes might partially account for the elevated antifibrotic effects on the fibrotic liver. Our study corroborated previous research by Ding et al. (<xref rid="jcp29176-bib-0011" ref-type="ref">2014</xref>), who showed that autophagy alleviates kidney fibrosis by regulating TGF&#x02010;&#x003b2;1 expression. However, one study showed that MSCs exert immunosuppressive effects in CD4<sup>+</sup> T lymphocytes via TGF&#x02010;&#x003b2;1 secretion and activation of autophagy (Gao et al., <xref rid="jcp29176-bib-0014" ref-type="ref">2016</xref>). The cause for this discrepancy may be associated with the molecular interplay between autophagy and immunity; indeed, autophagy functions in both activation and inactivation of immune signaling, thus balancing immune responses (Saitoh &#x00026; Akira, <xref rid="jcp29176-bib-0036" ref-type="ref">2010</xref>). Moreover, these discrepancies may be related to differences in the study designs, including tissue and species origins, cell isolation methods, T cell/MSC ratios, cell culture conditions, and time of data analysis.</p><p>The therapeutic effects of MSCs in inflammatory diseases is largely due to their unique capacity to secrete immunoregulatory factors (Ranganath, Levy, Inamdar, &#x00026; Karp, <xref rid="jcp29176-bib-0033" ref-type="ref">2012</xref>). Moreover, the colocalization of exogenous MSCs, T lymphocytes, and HSCs in the portal fibrotic area in CCl<sub>4</sub>&#x02010;induced fibrotic livers indicated that the inhibition of exogenous sh<italic>Becn1</italic>&#x02010;MSCs on proliferative capacity of HSCs and T lymphocytes might affect their immunosuppressive capability via a paracrine pathway, but not via hepatocyte regeneration. PGE<sub>2</sub> is an inflammation&#x02010;induced immunosuppressive agent secreted by MSCs, which mediates MSC&#x02010;dependent inhibition on T lymphocytes (M. Bai et al., <xref rid="jcp29176-bib-0005" ref-type="ref">2018</xref>). Notably, we found that knockdown of <italic>Becn1</italic> suppressed inflammation&#x02010;induced autophagy and generated more PTGS2/PGE<sub>2</sub> in MSCs, consistent with other studies. As outlined by Dang et al. (<xref rid="jcp29176-bib-0009" ref-type="ref">2014</xref>) cytokine&#x02010;induced autophagy affects the immunomodulatory properties of MSCs via the reactive oxygen species/mitogen&#x02010;activated protein kinase 1/3/PTGS2 pathway. Additionally, a study by O'Brien et al. (<xref rid="jcp29176-bib-0029" ref-type="ref">2014</xref>) also confirmed that acutely decompensated cirrhosis patients with reduced concentrations of serum PGE<sub>2</sub> displayed attenuated immune function and increased risk of infection. However, the immunomodulatory factors secreted by MSCs are highly changeable, likely because of their vigorous interactions with components of the immune system (Alfaifi et al., <xref rid="jcp29176-bib-0002" ref-type="ref">2018</xref>). MSCs can secrete various immunoinhibitive cytokines, including indoleamine 2,3&#x02010;dioxygenase, IL&#x02010;6, nitric oxide, and IL&#x02010;10 (Shi et al., <xref rid="jcp29176-bib-0039" ref-type="ref">2012</xref>). Therefore, we believe that there are other molecules involved in the mechanisms through which sh<italic>Becn1</italic>&#x02010;MSCs modulate T cells and PGE<sub>2</sub>, and these factors should be investigated in the future. Blocked autophagy may cause cellular senescence (Ma et al., <xref rid="jcp29176-bib-0026" ref-type="ref">2018</xref>) and increase the risk of tumor formation (Aita et al., <xref rid="jcp29176-bib-0001" ref-type="ref">1999</xref>; Levy et al., <xref rid="jcp29176-bib-0023" ref-type="ref">2014</xref>; Qu et al., <xref rid="jcp29176-bib-0032" ref-type="ref">2003</xref>; Wang et al., <xref rid="jcp29176-bib-0046" ref-type="ref">2019</xref>). Autophagy levels are significantly reduced in aging bone marrow MSCs. In turn, elevated activity of autophagy can partially reverse this senescence and restore bone loss in aged mice. Under certain conditions, loss of the <italic>Becn1</italic> gene in mice promotes tumorigenesis (Qu et al., <xref rid="jcp29176-bib-0032" ref-type="ref">2003</xref>). In many human tumors, including breast, ovarian, and prostate cancers, the <italic>Becn1</italic> gene is often partially deleted (Aita et al., <xref rid="jcp29176-bib-0001" ref-type="ref">1999</xref>). These findings indicate that controlling the autophagic activity by genetic manipulation may affect the stem&#x02010;like characteristics and differentiation functions of MSCs and increase the risk of tumor formation. Therefore, in future studies, it will be necessary to develop a safe and stable method for regulating autophagy.</p></sec><sec id="jcp29176-sec-0260"><label>5</label><title>CONCLUSIONS</title><p>In summary, our results confirmed, for the first time, that the LF microenvironment impeded the antifibrotic effects of MSCs by inducing autophagy. However, counteracting microenvironment&#x02010;induced autophagy promoted the antifibrotic effect of MSCs in CCl<sub>4</sub>&#x02010;induced LF. The boosted antifibrotic potential primed by autophagy inhibition in MSCs may be attributed to their suppressive effect on CD4<sup>+</sup> and CD8<sup>+</sup> lymphocytes infiltration and HSCs proliferation, which were regulated by elevated PTGS2/PGE<sub>2</sub> via a paracrine pathway. Our data support autophagy as a putative new therapeutic target for MSC&#x02010;based remedy in LF and other inflammatory disorders (Figure <xref rid="jcp29176-fig-0007" ref-type="fig">7</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jcp29176-fig-0007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Schematic illustration of the proposed model depicting how autophagy suppression enhanced the antifibrotic effect of mesenchymal stem cells (MSCs) under the context of liver fibrosis (LF). LF involves chronic inflammation&#x02010;induced parenchymal cell injury and activation of consequent repair processes executed by primed myofibroblasts progenitors. Based on our findings, the transplanted MSCs undergo autophagy in the LF microenvironment, and counteracting the microenvironment&#x02010;induced autophagy by <italic>Becn1</italic> knockdown promotes the antifibrotic effects of MSCs on CCl<sub>4</sub>&#x02010;induced LF. The enhanced antifibrotic potential primed by autophagy inhibition in MSCs may be attributed to their dual inhibitory effects on CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocyte infiltration and hepatic stellate cells (HSCs) and Gli1<sup>+</sup> cell proliferation, which may be regulated by elevated paracrine secretion of PTGS2/PGE<sub>2</sub>. PGE<sub>2</sub>,&#x000a0;prostaglandin E<sub>2</sub>; PTGS2, prostaglandin&#x02010;endoperoxide synthase 2 [Color figure can be viewed at wileyonlinelibrary.com]</p></caption><graphic id="nlm-graphic-15" xlink:href="JCP-235-2722-g007"/></fig></sec><sec sec-type="COI-statement" id="jcp29176-sec-0280"><title>CONFLICT OF INTERESTS</title><p>The authors declare that there are no conflict of interests.</p></sec><sec id="jcp29176-sec-0290"><title>AUTHOR CONTRIBUTIONS</title><p>Conceived and designed the experiments: Y. L. L. Performed the experiments: H. Y. W., J. S., C. L., W. H. L., F. M. D., J. W., Y. M., K. A. H., L. N. G., D. H. K., and Q. L. Analyzed the data: Y. L. L., J. S., C. L., H. Y. W., and W. H. L. Wrote the paper: Y. L. L., J. S., H. Y. W., and C. L. All authors read and approved the final version of the manuscript.</p></sec><sec id="jcp29176-sec-0300"><title>DATA ACCESSIBILITY</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><caption><p>Supporting information</p></caption><media xlink:href="JCP-235-2722-s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="jcp29176-sec-0270"><title>ACKNOWLEDGMENTS</title><p>The authors thank Dr. Hao Ran Tai for excellent technical support. This study was funded by the National Natural Science Foundation of China (grant nos. 81570558 and 81560566), Applied Basic Research Programs of Science and Technology Department of Sichuan Province (grant nos. 2017JY0304 and 2017JY0150), and Scientific Research Project of the Development and Regeneration Key Laboratory of Sichuan Province (grant nos. SYS15&#x02010;004 and SYS15&#x02010;008).</p></ack><ref-list id="jcp29176-bibl-0001"><ref-list id="jcp29176-bibSec-0001" content-type="cited-references"><title>REFERENCES</title><ref id="jcp29176-bib-0001"><mixed-citation publication-type="journal" id="jcp29176-cit-0001">
<string-name>
<surname>Aita</surname>, <given-names>V. M.</given-names>
</string-name>, <string-name>
<surname>Liang</surname>, <given-names>X. H.</given-names>
</string-name>, <string-name>
<surname>Murty</surname>, <given-names>V. V.</given-names>
</string-name>, <string-name>
<surname>Pincus</surname>, <given-names>D. L.</given-names>
</string-name>, <string-name>
<surname>Yu</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Cayanis</surname>, <given-names>E.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Levine</surname>, <given-names>B.</given-names>
</string-name> (<year>1999</year>). <article-title>Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21</article-title>. <source xml:lang="en">Genomics</source>, <volume>59</volume>, <fpage>59</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1006/geno.1999.5851</pub-id>
<pub-id pub-id-type="pmid">10395800</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0002"><mixed-citation publication-type="journal" id="jcp29176-cit-0002">
<string-name>
<surname>Alfaifi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Eom</surname>, <given-names>Y. W.</given-names>
</string-name>, <string-name>
<surname>Newsome</surname>, <given-names>P. N.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Baik</surname>, <given-names>S. K.</given-names>
</string-name> (<year>2018</year>). <article-title>Mesenchymal stromal cell therapy for liver diseases</article-title>. <source xml:lang="en">Journal of Hepatology</source>, <volume>68</volume>, <fpage>1272</fpage>&#x02013;<lpage>1285</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2018.01.030</pub-id>
<pub-id pub-id-type="pmid">29425678</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0003"><mixed-citation publication-type="journal" id="jcp29176-cit-0003">
<string-name>
<surname>Antonioli</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Di Rienzo</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Piacentini</surname>, <given-names>M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Fimia</surname>, <given-names>G. M.</given-names>
</string-name> (<year>2017</year>). <article-title>Emerging mechanisms in initiating and terminating autophagy</article-title>. <source xml:lang="en">Trends in Biochemical Sciences</source>, <volume>42</volume>, <fpage>28</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2016.09.008</pub-id>
<pub-id pub-id-type="pmid">27765496</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0004"><mixed-citation publication-type="journal" id="jcp29176-cit-0004">
<string-name>
<surname>Bai</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Lennon</surname>, <given-names>D. P.</given-names>
</string-name>, <string-name>
<surname>Caplan</surname>, <given-names>A. I.</given-names>
</string-name>, <string-name>
<surname>DeChant</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hecker</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Kranso</surname>, <given-names>J.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Miller</surname>, <given-names>R. H.</given-names>
</string-name> (<year>2012</year>). <article-title>Hepatocyte growth factor mediates mesenchymal stem cell&#x02010;induced recovery in multiple sclerosis models</article-title>. <source xml:lang="en">Nature Neuroscience</source>, <volume>15</volume>, <fpage>862</fpage>&#x02013;<lpage>870</lpage>. <pub-id pub-id-type="doi">10.1038/nn.3109</pub-id>
<pub-id pub-id-type="pmid">22610068</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0005"><mixed-citation publication-type="journal" id="jcp29176-cit-0005">
<string-name>
<surname>Bai</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Fu</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Bai</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Cai</surname>, <given-names>G.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Chen</surname>, <given-names>X.</given-names>
</string-name> (<year>2018</year>). <article-title>IL&#x02010;17A improves the efficacy of mesenchymal stem cells in ischemic&#x02010;reperfusion renal injury by increasing Treg percentages by the COX&#x02010;2/PGE2 pathway</article-title>. <source xml:lang="en">Kidney International</source>, <volume>93</volume>, <fpage>814</fpage>&#x02013;<lpage>825</lpage>. <pub-id pub-id-type="doi">10.1016/j.kint.2017.08.030</pub-id>
<pub-id pub-id-type="pmid">29132705</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0006"><mixed-citation publication-type="journal" id="jcp29176-cit-0006">
<string-name>
<surname>Cadwell</surname>, <given-names>K.</given-names>
</string-name> (<year>2016</year>). <article-title>Crosstalk between autophagy and inflammatory signaling pathways: Balancing defence and homeostasis</article-title>. <source xml:lang="en">Nature Reviews Immunology</source>, <volume>16</volume>, <fpage>661</fpage>&#x02013;<lpage>675</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2016.100</pub-id>
</mixed-citation></ref><ref id="jcp29176-bib-0007"><mixed-citation publication-type="journal" id="jcp29176-cit-0007">
<string-name>
<surname>Clarke</surname>, <given-names>A. J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Simon</surname>, <given-names>A. K.</given-names>
</string-name> (<year>2018</year>). <article-title>Autophagy in the renewal, differentiation and homeostasis of immune cells</article-title>. <source xml:lang="en">Nature Reviews Immunology</source>, <volume>19</volume>, <fpage>170</fpage>&#x02013;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1038/s-41577-018-0095-2</pub-id>
</mixed-citation></ref><ref id="jcp29176-bib-0008"><mixed-citation publication-type="journal" id="jcp29176-cit-0008">
<string-name>
<surname>Consentius</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Reinke</surname>, <given-names>P.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Volk</surname>, <given-names>H. D.</given-names>
</string-name> (<year>2015</year>). <article-title>Immunogenicity of allogeneic mesenchymal stromal cells: What has been seen in vitro and in vivo?</article-title>
<source xml:lang="en">Regenerative Medicine</source>, <volume>10</volume>, <fpage>305</fpage>&#x02013;<lpage>315</lpage>. <pub-id pub-id-type="doi">10.2217/rme.15.14</pub-id>
<pub-id pub-id-type="pmid">25933239</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0009"><mixed-citation publication-type="journal" id="jcp29176-cit-0009">
<string-name>
<surname>Dang</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Cai</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>, <given-names>Y.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Zhang</surname>, <given-names>Y.</given-names>
</string-name> (<year>2014</year>). <article-title>Autophagy regulates the therapeutic potential of mesenchymal stem cells in experimental autoimmune encephalomyelitis</article-title>. <source xml:lang="en">Autophagy</source>, <volume>10</volume>, <fpage>1301</fpage>&#x02013;<lpage>1315</lpage>. <pub-id pub-id-type="doi">10.4161/auto.28771</pub-id>
<pub-id pub-id-type="pmid">24905997</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0010"><mixed-citation publication-type="journal" id="jcp29176-cit-0010">
<string-name>
<surname>Deretic</surname>, <given-names>V.</given-names>
</string-name> (<year>2012</year>). <article-title>Autophagy: An emerging immunological paradigm</article-title>. <source xml:lang="en">Journal of Immunology</source>, <volume>189</volume>, <fpage>15</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1102108</pub-id>
</mixed-citation></ref><ref id="jcp29176-bib-0011"><mixed-citation publication-type="journal" id="jcp29176-cit-0011">
<string-name>
<surname>Ding</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>S. L.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>S. Y.</given-names>
</string-name>, <string-name>
<surname>Koo</surname>, <given-names>J. K.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>Z.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Choi</surname>, <given-names>M. E.</given-names>
</string-name> (<year>2014</year>). <article-title>Autophagy regulates TGF&#x02010;&#x003b2; expression and suppresses kidney fibrosis induced by unilateral ureteral obstruction</article-title>. <source xml:lang="en">Journal of the American Society of Nephrology</source>, <volume>25</volume>, <fpage>2835</fpage>&#x02013;<lpage>2846</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2013101068</pub-id>
<pub-id pub-id-type="pmid">24854279</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0012"><mixed-citation publication-type="journal" id="jcp29176-cit-0012">
<string-name>
<surname>Djavaheri&#x02010;Mergny</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Amelotti</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Mathieu</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Besan&#x000e7;on</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Bauvy</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Souqu&#x000e8;re</surname>, <given-names>S.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Codogno</surname>, <given-names>P.</given-names>
</string-name> (<year>2006</year>). <article-title>NF&#x02010;kappaB activation represses tumor necrosis factor&#x02010;alpha&#x02010;induced autophagy</article-title>. <source xml:lang="en">Journal of Biological Chemistry</source>, <volume>281</volume>, <fpage>30373</fpage>&#x02013;<lpage>30382</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M602097200</pub-id>
<pub-id pub-id-type="pmid">16857678</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0013"><mixed-citation publication-type="journal" id="jcp29176-cit-0013">
<string-name>
<surname>Fujio</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Komai</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Inoue</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Morita</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Okamura</surname>, <given-names>T.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Yamamoto</surname>, <given-names>K.</given-names>
</string-name> (<year>2016</year>). <article-title>Revisiting the regulatory roles of the TGF&#x02010;&#x003b2; family of cytokines</article-title>. <source xml:lang="en">Autoimmunity Reviews</source>, <volume>15</volume>, <fpage>917</fpage>&#x02013;<lpage>922</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev</pub-id>
<pub-id pub-id-type="pmid">27392504</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0014"><mixed-citation publication-type="journal" id="jcp29176-cit-0014">
<string-name>
<surname>Gao</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Cen</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Xie</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Deng</surname>, <given-names>W.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Shen</surname>, <given-names>H.</given-names>
</string-name> (<year>2016</year>). <article-title>Autophagy improves the immunosuppress on of CD4+ T cells by mesenchymal stem cells through transforming growth factor&#x02010;&#x003b2;1</article-title>. <source xml:lang="en">Stem Cells Translational Medicine</source>, <volume>5</volume>, <fpage>1496</fpage>&#x02013;<lpage>1505</lpage>. <pub-id pub-id-type="doi">10.5966/sctm.2015-0420</pub-id>
<pub-id pub-id-type="pmid">27400793</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0015"><mixed-citation publication-type="journal" id="jcp29176-cit-0015">
<string-name>
<surname>Ge</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Huang</surname>, <given-names>M.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Yao</surname>, <given-names>Y. M.</given-names>
</string-name> (<year>2018</year>). <article-title>Autophagy and proinflammatory cytokines: Interactions and clinical implications</article-title>. <source xml:lang="en">Cytokine and Growth Factor Reviews</source>, <volume>43</volume>, <fpage>38</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.cytogfr</pub-id>
<pub-id pub-id-type="pmid">30031632</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0016"><mixed-citation publication-type="journal" id="jcp29176-cit-0016">
<string-name>
<surname>Ghavami</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Cunnington</surname>, <given-names>R. H.</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Yeganeh</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Filomeno</surname>, <given-names>K. L.</given-names>
</string-name>, <string-name>
<surname>Freed</surname>, <given-names>D. H.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Dixon</surname>, <given-names>I. M. C.</given-names>
</string-name> (<year>2015</year>). <article-title>Autophagy is a regulator of TGF&#x02010;&#x003b2;1&#x02010;induced fibrogenesis in primary human atrial myofibroblasts</article-title>. <source xml:lang="en">Cell Death &#x00026; Disease</source>, <volume>6</volume>, <elocation-id>e1696</elocation-id>
<pub-id pub-id-type="doi">10.1038/cddis.2015.36</pub-id>
<pub-id pub-id-type="pmid">25789971</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0017"><mixed-citation publication-type="journal" id="jcp29176-cit-0017">
<string-name>
<surname>Han</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<surname>Lin</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>X.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Shi</surname>, <given-names>Y.</given-names>
</string-name> (<year>2014</year>). <article-title>Interleukin&#x02010;17 enhances immunosuppression by mesenchymal stem cells</article-title>. <source xml:lang="en">Cell Death and Differentiation</source>, <volume>21</volume>, <fpage>1758</fpage>&#x02013;<lpage>1768</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2014.85</pub-id>
<pub-id pub-id-type="pmid">25034782</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0018"><mixed-citation publication-type="journal" id="jcp29176-cit-0018">
<string-name>
<surname>Hao</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Shi</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Qian</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Sun</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>D.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Piao</surname>, <given-names>F.</given-names>
</string-name> (<year>2018</year>). <article-title>Bone marrow mesenchymal stem cells protect against n&#x02010;hexane&#x02010;induced neuropathy through beclin 1&#x02010;independent inhibition of autophagy</article-title>. <source xml:lang="en">Scientific Reports</source>, <volume>8</volume>, <fpage>4516</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-22857-x</pub-id>
<pub-id pub-id-type="pmid">29540747</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0019"><mixed-citation publication-type="journal" id="jcp29176-cit-0019">
<string-name>
<surname>Horton</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Hudak</surname>, <given-names>K. E.</given-names>
</string-name>, <string-name>
<surname>Chung</surname>, <given-names>E. J.</given-names>
</string-name>, <string-name>
<surname>White</surname>, <given-names>A. O.</given-names>
</string-name>, <string-name>
<surname>Scroggins</surname>, <given-names>B. T.</given-names>
</string-name>, <string-name>
<surname>Burkeen</surname>, <given-names>J. F.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Citrin</surname>, <given-names>D. E.</given-names>
</string-name> (<year>2013</year>). <article-title>Mesenchymal stem cells inhibit cutaneous radiation&#x02010;induced fibrosis by suppressing chronic inflammation</article-title>. <source xml:lang="en">Stem Cells</source>, <volume>31</volume>, <fpage>2231</fpage>&#x02013;<lpage>2241</lpage>. <pub-id pub-id-type="doi">10.1002/stem.1483</pub-id>
<pub-id pub-id-type="pmid">23897677</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0020"><mixed-citation publication-type="journal" id="jcp29176-cit-0020">
<string-name>
<surname>Jia</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>He</surname>, <given-names>M. X.</given-names>
</string-name>, <string-name>
<surname>McLeod</surname>, <given-names>I. X.</given-names>
</string-name>, <string-name>
<surname>Guo</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Ji</surname>, <given-names>D.</given-names>
</string-name>, &#x00026; <string-name>
<surname>He</surname>, <given-names>Y. W.</given-names>
</string-name> (<year>2015</year>). <article-title>Autophagy regulates T lymphocyte proliferation through selective degradation of the cell&#x02010;cycle inhibitor CDKN1B/p27Kip1</article-title>. <source xml:lang="en">Autophagy</source>, <volume>11</volume>, <fpage>2335</fpage>&#x02013;<lpage>2345</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2015.1110666</pub-id>
<pub-id pub-id-type="pmid">26569626</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0021"><mixed-citation publication-type="journal" id="jcp29176-cit-0021">
<string-name>
<surname>Kramann</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>, <given-names>R. K.</given-names>
</string-name>, <string-name>
<surname>DiRocco</surname>, <given-names>D. P.</given-names>
</string-name>, <string-name>
<surname>Machado</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Fleig</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Bondzie</surname>, <given-names>P. A.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Humphreys</surname>, <given-names>B. D.</given-names>
</string-name> (<year>2015</year>). <article-title>Perivascular gli1(+) progenitors are key contributors to injury&#x02010;induced organ fibrosis</article-title>. <source xml:lang="en">Cell Stem Cell</source>, <volume>16</volume>, <fpage>51</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.stem.2014.11.004</pub-id>
<pub-id pub-id-type="pmid">25465115</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0022"><mixed-citation publication-type="journal" id="jcp29176-cit-0022">
<string-name>
<surname>Lee</surname>, <given-names>Y. A.</given-names>
</string-name>, <string-name>
<surname>Wallace</surname>, <given-names>M. C.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Friedman</surname>, <given-names>S. L.</given-names>
</string-name> (<year>2015</year>). <article-title>Pathobiology of liver fibrosis: A translational success story</article-title>. <source xml:lang="en">Gut</source>, <volume>64</volume>, <fpage>830</fpage>&#x02013;<lpage>841</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2014-306842</pub-id>
<pub-id pub-id-type="pmid">25681399</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0023"><mixed-citation publication-type="journal" id="jcp29176-cit-0023">
<string-name>
<surname>Levy</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>, <given-names>J. C.</given-names>
</string-name>, <string-name>
<surname>Griesinger</surname>, <given-names>A. M.</given-names>
</string-name>, <string-name>
<surname>Amani</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Donson</surname>, <given-names>A. M.</given-names>
</string-name>, <string-name>
<surname>Birks</surname>, <given-names>D. K.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Thorburn</surname>, <given-names>A.</given-names>
</string-name> (<year>2014</year>). <article-title>Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors</article-title>. <source xml:lang="en">Cancer Discovery</source>, <volume>4</volume>, <fpage>773</fpage>&#x02013;<lpage>780</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-0049</pub-id>
<pub-id pub-id-type="pmid">24823863</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0024"><mixed-citation publication-type="journal" id="jcp29176-cit-0024">
<string-name>
<surname>Liu</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Xia</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>J.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Guo</surname>, <given-names>C.</given-names>
</string-name> (<year>2018</year>). <article-title>Alleviation of hepatic fibrosis and autophagy via inhibition of transforming growth factor&#x02010;&#x003b2;1_Smads pathway through shikonin</article-title>. <source xml:lang="en">Journal of Gastroenterology and Hepatology</source>, <volume>34</volume>, <fpage>263</fpage>&#x02013;<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1111/jgh.14299</pub-id>
<pub-id pub-id-type="pmid">29864192</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0025"><mixed-citation publication-type="journal" id="jcp29176-cit-0025">
<string-name>
<surname>Liu</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Kikuiri</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Akiyama</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>X.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Shi</surname>, <given-names>S.</given-names>
</string-name> (<year>2011</year>). <article-title>Mesenchymal stem cell&#x02010;based tissue regeneration is governed by recipient T lymphocytes via IFN&#x02010;&#x003b3; and TNF&#x02010;&#x003b1;</article-title>. <source xml:lang="en">Nature Medicine</source>, <volume>17</volume>, <fpage>1594</fpage>&#x02013;<lpage>1601</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2542</pub-id>
</mixed-citation></ref><ref id="jcp29176-bib-0026"><mixed-citation publication-type="journal" id="jcp29176-cit-0026">
<string-name>
<surname>Ma</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Qi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>An</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Doro</surname>, <given-names>D. H.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Jin</surname>, <given-names>Y.</given-names>
</string-name> (<year>2018</year>). <article-title>Autophagy controls mesenchymal stem cell properties and senescence during bone aging</article-title>. <source xml:lang="en">Aging Cell</source>, <volume>17</volume>, <elocation-id>e12709</elocation-id>
<pub-id pub-id-type="doi">10.1111/acel.12709</pub-id>
</mixed-citation></ref><ref id="jcp29176-bib-0027"><mixed-citation publication-type="journal" id="jcp29176-cit-0027">
<string-name>
<surname>Meng</surname>, <given-names>X. M.</given-names>
</string-name>, <string-name>
<surname>Nikolic&#x02010;Paterson</surname>, <given-names>D. J.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Lan</surname>, <given-names>H. Y.</given-names>
</string-name> (<year>2016</year>). <article-title>TGF&#x02010;&#x003b2;1: The master regulator of fibrosis</article-title>. <source xml:lang="en">Nature Reviews Nephrology</source>, <volume>12</volume>, <fpage>325</fpage>&#x02013;<lpage>338</lpage>. <pub-id pub-id-type="doi">10.1038/nrneph.2016.48</pub-id>
<pub-id pub-id-type="pmid">27108839</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0028"><mixed-citation publication-type="journal" id="jcp29176-cit-0028">
<string-name>
<surname>Mougiakakos</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Jitschin</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Johansson</surname>, <given-names>C. C.</given-names>
</string-name>, <string-name>
<surname>Okita</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Kiessling</surname>, <given-names>R.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Le Blanc</surname>, <given-names>K.</given-names>
</string-name> (<year>2011</year>). <article-title>The impact of inflammatory licensing on heme oxygenase&#x02010;1&#x02010;mediated induction of regulatory T cells by human mesenchymal stem cells</article-title>. <source xml:lang="en">Blood</source>, <volume>117</volume>, <fpage>4826</fpage>&#x02013;<lpage>4835</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2010-12-324038</pub-id>
<pub-id pub-id-type="pmid">21389316</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0029"><mixed-citation publication-type="journal" id="jcp29176-cit-0029">
<string-name>
<surname>O'Brien</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Fullerton</surname>, <given-names>J. N.</given-names>
</string-name>, <string-name>
<surname>Massey</surname>, <given-names>K. A.</given-names>
</string-name>, <string-name>
<surname>Auld</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Sewell</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>James</surname>, <given-names>S.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Gilroy</surname>, <given-names>D. W.</given-names>
</string-name> (<year>2014</year>). <article-title>Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2</article-title>. <source xml:lang="en">Nature Medicine</source>, <volume>20</volume>, <fpage>518</fpage>&#x02013;<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3516</pub-id>
</mixed-citation></ref><ref id="jcp29176-bib-0030"><mixed-citation publication-type="journal" id="jcp29176-cit-0030">
<string-name>
<surname>Pesce</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Kaviratne</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Ramalingam</surname>, <given-names>T. R.</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>, <given-names>R. W.</given-names>
</string-name>, <string-name>
<surname>Urban</surname>, <given-names>J. F.</given-names>, <suffix>Jr.</suffix>
</string-name>, <string-name>
<surname>Cheever</surname>, <given-names>A. W.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Wynn</surname>, <given-names>T. A.</given-names>
</string-name> (<year>2006</year>). <article-title>The IL&#x02010;21 receptor augments Th2 effector function and alternative macrophage activation</article-title>. <source xml:lang="en">Journal of Clinical Investigation</source>, <volume>116</volume>, <fpage>2044</fpage>&#x02013;<lpage>2055</lpage>. <pub-id pub-id-type="doi">10.1172/JCI27727</pub-id>
<pub-id pub-id-type="pmid">16778988</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0031"><mixed-citation publication-type="journal" id="jcp29176-cit-0031">
<string-name>
<surname>Puche</surname>, <given-names>J. E.</given-names>
</string-name>, <string-name>
<surname>Saiman</surname>, <given-names>Y.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Friedman</surname>, <given-names>S. L.</given-names>
</string-name> (<year>2013</year>). <article-title>Hepatic stellate cells and liver fibrosis</article-title>. <source xml:lang="en">Comprehensive Physiology</source>, <volume>3</volume>, <fpage>1473</fpage>&#x02013;<lpage>1492</lpage>. <pub-id pub-id-type="doi">10.1002/cphy.c120035</pub-id>
<pub-id pub-id-type="pmid">24265236</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0032"><mixed-citation publication-type="journal" id="jcp29176-cit-0032">
<string-name>
<surname>Qu</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Yu</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Bhagat</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Furuya</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Hibshoosh</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Troxel</surname>, <given-names>A.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Levine</surname>, <given-names>B.</given-names>
</string-name> (<year>2003</year>). <article-title>Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene</article-title>. <source xml:lang="en">Journal of Clinical Investigation</source>, <volume>112</volume>, <fpage>1809</fpage>&#x02013;<lpage>1820</lpage>. <pub-id pub-id-type="doi">10.1172/JCI20039</pub-id>
<pub-id pub-id-type="pmid">14638851</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0033"><mixed-citation publication-type="journal" id="jcp29176-cit-0033">
<string-name>
<surname>Ranganath</surname>, <given-names>S. H.</given-names>
</string-name>, <string-name>
<surname>Levy</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Inamdar</surname>, <given-names>M. S.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Karp</surname>, <given-names>J. M.</given-names>
</string-name> (<year>2012</year>). <article-title>Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease</article-title>. <source xml:lang="en">Cell Stem Cell</source>, <volume>10</volume>, <fpage>244</fpage>&#x02013;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1016/j.stem.2012.02.005</pub-id>
<pub-id pub-id-type="pmid">22385653</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0034"><mixed-citation publication-type="journal" id="jcp29176-cit-0034">
<string-name>
<surname>Ren</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Xu</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>, <given-names>A. I.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Shi</surname>, <given-names>Y.</given-names>
</string-name> (<year>2008</year>). <article-title>Mesenchymal stem cell mediated immunosuppression occurs via concerted action of chemokines and nitric oxide</article-title>. <source xml:lang="en">Cell Stem Cell</source>, <volume>2</volume>, <fpage>141</fpage>&#x02013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1016/j.stem.2007.11.014</pub-id>
<pub-id pub-id-type="pmid">18371435</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0035"><mixed-citation publication-type="journal" id="jcp29176-cit-0035">
<string-name>
<surname>Rocheteau</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Chatre</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Briand</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Mebarki</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Jouvion</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Bardon</surname>, <given-names>J.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Chr&#x000e9;tien</surname>, <given-names>F.</given-names>
</string-name> (<year>2015</year>). <article-title>Sepsis induces long&#x02010;term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapy</article-title>. <source xml:lang="en">Nature Communications</source>, <volume>6</volume>, <fpage>10145</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms10145</pub-id>. <ext-link ext-link-type="uri" xlink:href="https://dx.d-oi.org/">https://dx.d-oi.org/</ext-link>
</mixed-citation></ref><ref id="jcp29176-bib-0036"><mixed-citation publication-type="journal" id="jcp29176-cit-0036">
<string-name>
<surname>Saitoh</surname>, <given-names>T.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Akira</surname>, <given-names>S.</given-names>
</string-name> (<year>2010</year>). <article-title>Regulation of innate immune responses by autophagy&#x02010;related proteins</article-title>. <source xml:lang="en">Journal of Cell Biology</source>, <volume>189</volume>, <fpage>925</fpage>&#x02013;<lpage>935</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.20-1002021</pub-id>
<pub-id pub-id-type="pmid">20548099</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0037"><mixed-citation publication-type="journal" id="jcp29176-cit-0037">
<string-name>
<surname>Seki</surname>, <given-names>E.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Schwabe</surname>, <given-names>R. F.</given-names>
</string-name> (<year>2015</year>). <article-title>Hepatic inflammation and fibrosis: Functional links and key pathways</article-title>. <source xml:lang="en">Hepatology</source>, <volume>61</volume>, <fpage>1066</fpage>&#x02013;<lpage>1079</lpage>. <pub-id pub-id-type="doi">10.1002/hep.27332</pub-id>
<pub-id pub-id-type="pmid">25066777</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0038"><mixed-citation publication-type="journal" id="jcp29176-cit-0038">
<string-name>
<surname>Shi</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Hu</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Su</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<surname>Shou</surname>, <given-names>P.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Ren</surname>, <given-names>G.</given-names>
</string-name> (<year>2010</year>). <article-title>Mesenchymal stem cells: A new strategy for immunosuppression and tissue repair</article-title>. <source xml:lang="en">Cell Research</source>, <volume>20</volume>, <fpage>510</fpage>&#x02013;<lpage>518</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2010.44</pub-id>
<pub-id pub-id-type="pmid">20368733</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0039"><mixed-citation publication-type="journal" id="jcp29176-cit-0039">
<string-name>
<surname>Shi</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Su</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>, <given-names>A. I.</given-names>
</string-name>, <string-name>
<surname>Shou</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Rabson</surname>, <given-names>A. B.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Ren</surname>, <given-names>G.</given-names>
</string-name> (<year>2012</year>). <article-title>How mesenchymal stem cells interact with tissue immune responses</article-title>. <source xml:lang="en">Trends in Immunology</source>, <volume>33</volume>, <fpage>136</fpage>&#x02013;<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2011.11.004</pub-id>
<pub-id pub-id-type="pmid">22227317</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0040"><mixed-citation publication-type="journal" id="jcp29176-cit-0040">
<string-name>
<surname>Shibutani</surname>, <given-names>S. T.</given-names>
</string-name>, <string-name>
<surname>Saitoh</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Nowag</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>M&#x000fc;nz</surname>, <given-names>C.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Yoshimori</surname>, <given-names>T.</given-names>
</string-name> (<year>2015</year>). <article-title>Autophagy and autophagy&#x02010;related proteins in the immune system</article-title>. <source xml:lang="en">Nature Immunology</source>, <volume>16</volume>, <fpage>1014</fpage>&#x02013;<lpage>1024</lpage>. <pub-id pub-id-type="doi">10.1038/ni.3273</pub-id>
<pub-id pub-id-type="pmid">26382870</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0041"><mixed-citation publication-type="journal" id="jcp29176-cit-0041">
<string-name>
<surname>Swart</surname>, <given-names>J. F.</given-names>
</string-name>, <string-name>
<surname>de Roock</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Hofhuis</surname>, <given-names>F. M.</given-names>
</string-name>, <string-name>
<surname>Rozemuller</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>van den Broek</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Moerer</surname>, <given-names>P.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Wulffraat</surname>, <given-names>N. M.</given-names>
</string-name> (<year>2015</year>). <article-title>Mesenchymal stem cell therapy in proteoglycan induced arthritis</article-title>. <source xml:lang="en">Annals of the Rheumatic Diseases</source>, <volume>74</volume>, <fpage>769</fpage>&#x02013;<lpage>777</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2013-20414</pub-id>
<pub-id pub-id-type="pmid">24395558</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0042"><mixed-citation publication-type="journal" id="jcp29176-cit-0042">
<string-name>
<surname>Trautwein</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Friedman</surname>, <given-names>S. L.</given-names>
</string-name>, <string-name>
<surname>Schuppan</surname>, <given-names>D.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Pinzani</surname>, <given-names>M.</given-names>
</string-name> (<year>2015</year>). <article-title>Hepatic fibrosis: Concept to treatment</article-title>. <source xml:lang="en">Journal of Hepatology</source>, <volume>62</volume>, <fpage>S15</fpage>&#x02013;<lpage>S24</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2015.02.039</pub-id>
<pub-id pub-id-type="pmid">25920084</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0043"><mixed-citation publication-type="journal" id="jcp29176-cit-0043">
<string-name>
<surname>Tsuchida</surname>, <given-names>T.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Friedman</surname>, <given-names>S. L.</given-names>
</string-name> (<year>2017</year>). <article-title>Mechanisms of hepatic stellate cell activation</article-title>. <source xml:lang="en">Nature Reviews Gastroenterology &#x00026; Hepatology</source>, <volume>14</volume>, <fpage>397</fpage>&#x02013;<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1038/nrgastro.2017.38</pub-id>
<pub-id pub-id-type="pmid">28487545</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0044"><mixed-citation publication-type="journal" id="jcp29176-cit-0044">
<string-name>
<surname>Tu</surname>, <given-names>S. P.</given-names>
</string-name>, <string-name>
<surname>Quante</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Bhagat</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Takaishi</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Cui</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>X. D.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Wang</surname>, <given-names>T. C.</given-names>
</string-name> (<year>2011</year>). <article-title>IFN&#x02010;&#x003b3; inhibits gastric carcinogenesis by inducing epithelial cell autophagy and T&#x02010;cell apoptosis</article-title>. <source xml:lang="en">Cancer Research</source>, <volume>71</volume>, <fpage>4247</fpage>&#x02013;<lpage>4259</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-4009</pub-id>
<pub-id pub-id-type="pmid">21512143</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0045"><mixed-citation publication-type="journal" id="jcp29176-cit-0045">
<string-name>
<surname>Wang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Cao</surname>, <given-names>W.</given-names>
</string-name>, &#x00026; <string-name>
<surname>Shi</surname>, <given-names>Y.</given-names>
</string-name> (<year>2014</year>). <article-title>Plasticity of mesenchymal stem cells in immunomodulation: Pathological and therapeutic implications</article-title>. <source xml:lang="en">Nature Immunology</source>, <volume>15</volume>, <fpage>1009</fpage>&#x02013;<lpage>1016</lpage>. <pub-id pub-id-type="doi">10.1038/ni.3002</pub-id>
<pub-id pub-id-type="pmid">25329189</pub-id></mixed-citation></ref><ref id="jcp29176-bib-0046"><mixed-citation publication-type="journal" id="jcp29176-cit-0046">
<string-name>
<surname>Wang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Xiong</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Hill</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Ertay</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Li</surname>, <given-names>J.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Lu</surname>, <given-names>X.</given-names>
</string-name> (<year>2019</year>). <article-title>Autophagy inhibition specifically promotes epithelial&#x02010;mesenchymal transition and invasion in RAS&#x02010;mutated cancer cells</article-title>. <source xml:lang="en">Autophagy</source>, <volume>20</volume>, <fpage>1</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.20-19.1569912</pub-id>
</mixed-citation></ref><ref id="jcp29176-bib-0047"><mixed-citation publication-type="journal" id="jcp29176-cit-0047">
<string-name>
<surname>Wynn</surname>, <given-names>T. A.</given-names>
</string-name> (<year>2004</year>). <article-title>Fibrotic disease and the T(H)1/T(H)2 paradigm</article-title>. <source xml:lang="en">Nature Reviews Immunology</source>, <volume>4</volume>, <fpage>583</fpage>&#x02013;<lpage>594</lpage>. <pub-id pub-id-type="doi">10.1038/nri1412</pub-id>
</mixed-citation></ref><ref id="jcp29176-bib-0048"><mixed-citation publication-type="journal" id="jcp29176-cit-0048">
<string-name>
<surname>Yuan</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Ding</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Xia</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>H.</given-names>
</string-name>, &#x02026; <string-name>
<surname>Li</surname>, <given-names>B.</given-names>
</string-name> (<year>2018</year>). <article-title>TNF&#x02010;&#x003b1; induces autophagy through ERK1/2 pathway to regulate apoptosis in neonatal necrotizing enterocolitis model cells IEC&#x02010;6</article-title>. <source xml:lang="en">Cell Cycle</source>, <volume>17</volume>, <fpage>1390</fpage>&#x02013;<lpage>1402</lpage>. <pub-id pub-id-type="doi">10.1080/15384101.2018.1482150</pub-id>
<pub-id pub-id-type="pmid">29950141</pub-id></mixed-citation></ref></ref-list></ref-list></back></article>